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COGNITIVE AND OCCUPATIONAL FUNCTION IN SURVIVORS OF
ADOLESCENT CANCER
Bethany D. Nugent, PhD
University of Pittsburgh, 2016
The number of cancer survivors living in the U.S. is dramatically increasing. Cognitive de-
cline is a commonly reported and burdensome symptom of cancer survivors. In addition,
many cancer survivors experience difficulty maintaining employment. This dissertation ad-
dresses gaps in the literature of cognitive and occupational function of cancer survivors, with
particular emphasis on the understudied population of cancer survivors diagnosed as an ado-
lescent or young adult (AYA). For this dissertation, a series of studies were conducted to 1)
explore the association between occupation and symptom burden in breast cancer survivors,
2) synthesize the evidence of cognitive outcomes in survivors of AYA cancer, and 3) describe
cognitive and occupational function in survivors of adolescent cancer compared to healthy
controls.
To address aim one, a secondary analysis of data from early-stage breast cancer sur-
vivors explored the relationship between occupation and symptom burden. Breast cancer
survivors employed in lower skill level jobs reported greater symptom burden over the first
year of anastrozole treatment than women employed at the higher skill level. Survivors em-
ployed at lower skill levels had higher levels of fatigue and worse depressive, musculoskeletal,
vasomotor, and gastrointestinal symptoms.
To address aim two, an integrative review synthesized the current state of science in terms
of cognitive outcomes of those diagnosed with cancer as an AYA. Survivors of AYA cancer
tended to experience cognitive difficulties; however, to date, no study has focused exclusively
on those diagnosed as an AYA or encompassed the entirety of the AYA age range. Future
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studies are needed because cognitive outcomes of survivors of AYA cancer have been largely
neglected.
Lastly, a cross-sectional, descriptive comparative study described cognitive and occupa-
tional function in survivors of adolescent cancer compared to healthy controls. Survivors of
adolescent cancer perceived greater cognitive difficulty than healthy peers, although there
were not significant measurable differences in performance on neuropsychological tests. Sur-
vivors of adolescent cancer also reported poorer work output than healthy controls.
This dissertation contributes to the growing body of literature pertaining to health and
well-being of cancer survivors, in particular cognitive and occupational function, and unique
considerations needed for those diagnosed with cancer as an AYA.
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1.0 INTRODUCTION
An estimated 14.5 million survivors of cancer currently live in the U.S. (DeSantis et al., 2014)
By 2024, the number of cancer survivors is projected to increase dramatically, reaching ap-
proximately 19 million cancer survivors. (DeSantis et al., 2014) To better understand cancer
survivors’ concerns, The Office of Cancer Survivorship of the National Cancer Institute (NCI)
stresses the importance of examining understudied populations of cancer survivors, such as
adult survivors of adolescent and young adult (AYA) cancer. AYA cancer survivors, defined
as those diagnosed with cancer between the ages of 15 to 29 years (worldwide) or 15 to 39
years (United States) (American Cancer Society, 2012; Bleyer, Viny, & Barr, 2006; National
Cancer Institute & Lance Armstrong Foundation, 2006), are believed to experience unique
challenges related to school, work, and relationships with peers. However, most research and
guidelines about treatment recommendations for adult survivors of AYA cancer are based
on studies conducted in survivors of childhood cancer. Almost no research has been con-
ducted in adults diagnosed with cancer as adolescents, creating a gap in current knowledge
regarding best practices. With more adolescents surviving cancer into adulthood, it is be-
coming increasingly clear that these individuals encounter significant difficulty in regaining
the skills necessary to meet the demands of healthy adult development. Successful reentry
into work and school may be impacted by neurocognitive morbidities potentially impacting
occupational functioning. (Dieluweit et al., 2011) The ability to work has been shown to
improve cancer survivors’ quality of life, reduce social isolation, and increase self-esteem.
(Nieuwenhuijsen, de Boer, Spelten, Sprangers, & Verbeek, 2009; Spelten, 2002) A recent
study reported that survivors of AYA cancer are significantly more likely to experience dis-
ability and unemployment than healthy controls (24% vs. 14%) (Tai et al., 2012); however,
it is unclear why this disparity exists and what factors may be associated.
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The National Institute of Nursing Research (NINR) strategic goals address mitigating
the chronic burden of illness (such as cancer) as an important focus in anticipating future
challenges and improving patient quality of life. Studying adult survivors of adolescent cancer
is important because of the developmentally vulnerable time point in which a cancer diagnosis
and treatment are received. While peers are often completing high school education and
entering college or the workforce, AYA cancer patients are experiencing treatment that can
have devastating consequences. Studies of brain development show that the brain, especially
the frontal lobe, continues to mature and develop into the early twenties. (National Institute
of Mental Health, 2011) Cancer, cancer treatment, and its effects, such as changes in cognitive
function, could impair the typical neurological and behavioral development of the adolescent
patient and disrupt the adolescent survivor’s long term employment status as they move
into adulthood. Studies of childhood (Moore, 2005) and adult cancers (Calvio, Feuerstein,
Hansen, & Luff, 2009; Calvio, Peugeot, Bruns, Todd, & Feuerstein, 2010; Kadan-Lottick et
al., 2010) indicate disease- and treatment-related cognitive delays, but few systematically
include survivors of adolescent cancer.
Disability and unemployment from cognitive impairment can result in lost potential
and tremendous personal and societal costs. Yet, the impact of adolescent cancer and its
treatment on survivors’ cognitive function and occupational function has not been considered.
In 2006, the AYA Progress Review Group was assembled by the NCI to address research
and cancer care needs for patients in this age group. The progress review group recommends
supporting research to improve patient and survivor outcomes and to identify characteristics
that distinguish the unique cancer burden for AYA. (National Cancer Institute & Lance
Armstrong Foundation, 2006)
The direct contributions of this dissertation project are 1) expanding the understanding
of the relationship between occupational skill level and symptom experience in a cohort of
breast cancer survivors, 2) providing an overview of current state of the science regarding
cognitive function in survivors of adolescent and young adult cancers, and 3) presenting the
results of an original research study exploring cognitive and occupational function in adult
survivors of adolescent cancer.
Study 1. Maintaining occupational roles for cancer survivors is difficult, indeed; ap-
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proximately 40% of all cancer survivors never return to work (Spelten, 2002). Of cancer
survivors who remain working, up to 13% stop working within 4 years of diagnosis (Taskila
& Lindbohm, 2007). Disease and treatment-related symptoms may influence the ability of
cancer survivors to return to work, maintain pre-diagnosis levels of work productivity and
advance in careers. Few studies have examined the relationship between disease and treat-
ment symptoms and the ability to maintain occupational roles and no studies to date have
examined this relationship in postmenopausal women during aromatase inhibitor (AI) ther-
apy for early-stage breast cancer. The purpose of this study is to examine the association
of occupation and symptom experience in a cohort of breast cancer survivors. Data for this
study came from a secondary analysis of a longitudinal study examining cognitive function
in postmenopausal women with early-stage breast cancer receiving aromatase inhibitor (AI)
therapy (PI: Bender). This secondary analysis is important to the candidate’s program of
research because it examined similar concepts of interest, notably occupational roles, and
employed similar statistical methods to those planned in the candidate’s original research
study (Study 3).
Study 2. While there is a growing body of literature suggesting that many cancer sur-
vivors may experience cognitive decline after cancer diagnosis and treatment, much less is
known about the cognitive outcomes of those diagnosed during the AYA timeframe. There-
fore, the second study of this dissertation is an integrative review to summarize and appraise
the current state of published literature involving cognitive function in those diagnosed
during adolescence and young adulthood. While the review is a distinct study within the
dissertation project, it provides a critically important foundation for the candidate’s original
dissertation research that was conducted in Study 3.
Study 3. In this study, the candidate’s original research project is featured. This is
a cross-sectional descriptive, comparative study to explore cognitive function and occupa-
tional function in adult survivors of adolescent cancer. The specific aims of the study are
to 1) describe cognitive function (using objective and self-report measures) and ratings of
occupational function among adult survivors of adolescent cancer and 2) explore differences
in cognitive function (using objective and self-report measures) and occupational function
between adult survivors of adolescent cancer and age- and sex-matched healthy controls.
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The evidence obtained in this dissertation will contribute to the growing body of lit-
erature pertaining to the health and well-being of cancer survivors, in particular cognitive
changes and occupational function. Ultimately, the research conducted through this dis-
sertation is aimed at helping to describe and inform the needs of AYA cancer survivors, a
vulnerable, understudied population, and is envisioned as the first step in the development
of a program of research examining survivorship concerns of adult survivors of adolescent
cancer. Specifically, the knowledge gained from this study could be used to inform the devel-
opment of behavioral interventions aimed at promoting optimal cognitive and occupational
function in survivors of AYA cancer.
The methods (including study design, sample and setting, measures, statistical analysis)
for each study are described in detail in the body of each manuscript (see Chapter 3, 4,
and 5). Following the three manuscripts, an integrative summary of dissertation findings is
provided.
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2.0 PRELIMINARY WORK
Prior to entering the PhD program at the University of Pittsburgh School of Nursing, the
candidate (Nugent) had interest in better understanding how cancer and treatment during
adolescence and young adulthood affected the lifelong health and well-being of these cancer
survivors. Several experiences helped the candidate refine her ideas and formulate a research
question.
To gain a better understanding of AYA cancers, their treatments, and the unique con-
siderations for this population, the candidate enrolled in a year-long Graduate Certificate
program in Adolescent and Young Adult Oncology (one of only two programs offered world-
wide) through the University of Melbourne. This was a distance-learning program from
which she graduated in December, 2014. The candidate has also attended Survivorship
Clinic at Children’s Hospital of Pittsburgh of UPMC (under the mentorship of Dr. Jean
Tersak) since 2012 to gain a better understanding of survivorship concerns of young adult
cancer survivors. These training opportunities gave the candidate exposure to experts in
the fields of both AYA Oncology and in survivorship and assisted in the development of her
understanding of the unique challenges of this population.
Early on in her studies, a Graduate Student Research (GSR) position with Dr. Paula
Sherwood afforded the candidate the opportunity to examine work outcomes in a popula-
tion of skull base tumor patients. This experience resulted in a data-based paper entitled
Work productivity and neuropsychological function in persons with skull base tumors and
is published in the Journal of Neuro-Oncology Practice. (See Appendix A) The purpose
of this investigation was to evaluate the impact of cognitive function on work productivity
in persons with skull base tumors prior to resection. Depressive symptoms and cognitive
function (including the domains of attention and flexibility, visuospatial ability, and learn-
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ing and memory) were associated with difficulty meeting work demands and contributed to
overall health-related loss of work productivity. This project was influential in defining the
candidate’s research interest for the dissertation study because it exposed her to the con-
cept of occupational function in cancer survivors. One of the primary tasks of adolescence
and young adulthood from a psychosocial perspective is the furthering of education and/or
entering the workforce. This project helped to expose the candidate to the concept of both
occupational and cognitive function and the potential relationship between the two.
A later GSR position with Dr. Catherine Bender gave the candidate the opportunity
to assist in the development of a manuscript pertaining to the complex nature of cognitive
function among cancer survivors. This paper is entitled Cancer and cognitive function: The
complexity of the problem and is published in Seminars in Oncology Nursing (See Appendix
C). The purpose of this paper was to describe factors that influence cognitive function in the
context of cancer and cancer therapy and to illustrate the complex nature of the problem.
The paper describes multiple factors which contribute to changes in cognitive function in
this population including demographic, psychological, and physiological factors, the disease
itself, disease- and treatment- related symptoms, and the management of those symptoms.
Through involvement on this project the candidate gained a greater understanding of the
numerous factors impacting cognitive function and assisted her in choosing additional con-
founders and covariates when conducting her original research study, Study 3 of the disser-
tation.
2.1 DEMONSTRATION OF ABILITY TO RECRUIT SURVIVORS OF
ADOLESCENT CANCER
Through the work on her pilot study, the candidate demonstrated the ability to recruit sur-
vivors of adolescent cancer. She applied for and was successfully awarded a grant (University
of Pittsburgh School of Nursing Judith Erlen PhD Student Endowed Research Award) to
allow her to conduct a pilot study examining psychosocial development and the concepts
of posttraumatic stress and posttraumatic growth in survivors of adolescent cancer. (See
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Appendix E for IRB Approval Letters) During the course of two years, the candidate was
successfully able to recruit 49 patients to her cross-sectional descriptive study and demon-
strated that it was feasible to recruit survivors of AYA cancer for her dissertation study
through similar means. The findings from the candidate’s pilot study were presented through
podium presentations at two conferences (2013 Oncology Nursing Society and 2014 Council
for the Advancement of Nursing Science). These abstracts can be found in Appendix F and
G.
2.2 BSN-TO-PHD MILESTONES
The following table (Table 1) lists the milestones that have been achieved since entrance
into the BSN-to-PhD program at the University of Pittsburgh School of Nursing in August
2011. All milestones support the scientific merit of the proposed dissertation study.
Table 1: BSN-to-PhD Program Milestones
Milestone Date Interdisciplinary Training of Nurse Scientists in Cancer Survivorship Research (T32NR011972) fellowship appointment Aug 2011 Judith Erlen PhD Student Endowed Research Award Aug 2012 Preliminary Examination May 2013 University of Pittsburgh School of Nursing Bessie Li Sze Memorial Scholarship Aug 2013 University of Pittsburgh Institutional Review Board Approval for Cognitive and Occupational Function in Adult Survivors of Adolescent Cancer (Expedited Review; PRO13100151; Appendix H) Feb 2014 American Cancer Society Doctoral Degree Scholarship in Cancer Nursing (DSCN-14-079-01-SCN) July 2014 Cognitive Function and Work Productivity in Survivors of Adolescent Cancer (F31NR014958) Funded by National Institute of Nursing Research Aug 2014 Completed Graduate Certificate in Adolescent Health and Wellbeing Oncology Stream through the University of Melbourne Dec 2014 Comprehensive Examination and Overview May 2015 University of Pittsburgh School of Nursing Margaret E. Wilkes Scholarship Fund Award July 2015 Attendance at Clinical and Translational Research Course for PhD Students offered by the Clinical Center at the National Institute of Health July 2016  
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3.0 DISSERTATION MANUSCRIPT #1
THE ASSOCIATION BETWEEN PRE-TREATMENT OCCUPATIONAL
SKILL LEVEL AND MOOD AND SYMPTOM BURDERN IN
EARLY-STAGE, POSTEMENOPAUSAL BREAST CANCER SURVIVORS
DURING THE FIRST YEAR OF ANASTRAZOLE THERAPY
Purpose Previous research has explored occupational activity of breast cancer survivors but
has not examined the influence of occupational level on symptoms prospectively. The purpose
of this study was to examine the relationship between occupational classification and changes
in mood and symptomburden for postmenopausal breast cancer survivors during the first
year of anastrozole therapy.
Methods This was an exploratory secondary analysis in 49 postmenopausal women receiv-
ing anastrozole therapy for early-stage breast cancer. Participants reported their occupation
at baseline and completed self-report questionnaires measuring mood and symptom burden
at baseline, 6 months, and 12 months. Occupation was classified according to four major
skill levels delineated by the International Standard Classification of Occupations (ISCO).
Results Breast cancer survivors employed at occupational skill levels 1 through 3 reported
significantly higher depressive symptoms, fatigue, and total symptoms on average than those
employed at ISCO skill level 4. After adjusting for multiple comparisons, this pattern re-
mained for the musculoskeletal, vasomotor, and gastrointestinal symptom subscales.
Conclusions Breast cancer survivors employed at lower skill levels (i.e., ISCO 13) reported
poorer mood and greater symptom burden than breast cancer survivors employed at a higher
skill level (i.e., ISCO 4). Assessing baseline occupation of occupationally active breast cancer
survivors may improve understanding of the association between types of occupations and
mood and symptom trajectories and may inform development of interventions to mitigate
8
symptom severity in order to help breast cancer survivors maintain optimal occupational
function and adherence to therapy
The full text of this manuscript can be found in Appendix H as it has been published
prior to the submission of this dissertation document.
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4.0 DISSERTATION MANUSCRIPT #2
COGNITIVE FUNCTION IN SURVIVORS OF ADOLESCENT AND
YOUNG ADULT CANCER: AN INTEGRATIVE REVIEW AND
LITERATURE CRITIQUE
Purpose: This integrative review summarizes the current literature pertaining to cognitive
outcomes of those diagnosed with cancer as adolescents and young adults (AYA) (ages 15-24)
and provides direction for future research.
Methods: PubMed and PsycInfo were searched from inception until March, 2016. All En-
glish peer-review studies that included at least one individual diagnosed during the AYA age
range and a measurement of cognitive function (either patient perception of neurocognitive
testing) were included. All included studies were independently assessed by two investigators.
Results: Of the 646 articles identified, 17 studies were included. Most studies were
cross-sectional (62.6%) and measured patient perception of cognitive function without neu-
rocognitive testing (52.9%). Findings across studies varied widely although all generally
endorsed some degree of cognitive difficulty in cancer survivors which was influenced by can-
cer type, treatment received, and age at diagnosis. No study included in the review focused
either exclusively on those diagnosed as an AYA or encompassed the entirety of the AYA age
range. Common AYA cancers that were particularly underrepresented include carcinoma,
melanoma, and germ cell tumors.
Conclusions: Cancer survivors tended to experience cognitive difficulties; however, the
heterogeneity of the studies hindered strong conclusions. The current review highlights the
paucity of literature in this population. Research is needed to define unique characteristics
and neurocognitive outcomes in the AYA population given the disruption of life milestones
at a critical time point in development.
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Implications for Cancer Survivors: Cancer as an AYA might result in cognitive difficulties;
however, more research is needed as current evidence is scarce.
4.1 INTRODUCTION
Cognitive declines with cancer and cancer treatment are seen in 15% to 35% of all cancer
survivors, and some studies have reported levels as high as 75% (Ahles, Root, & Ryan, 2012;
Asher & Myers, 2015; Janelsins et al., 2011). Although some researchers focus exclusively on
the effect of treatment on cognitive function, cognitive difficulties have been observed prior
to the initiation of treatment for cancer (Bender et al., 2015; Berman et al., 2014; Pullens,
De Vries, & Roukema, 2010; Wefel, Vidrine, et al., 2011). These findings suggest that
both treatment for cancer and even cancer itself may influence cognitive function. Cognitive
impairment and declines in cognitive function can have long-term negative effects such as
poorer quality of life and as well as a major impact on a survivor’s education and career
plans (Ahles et al., 2012; R. Ferguson & Ahles, 2003; Krull et al., 2012).
Despite earlier theories that brain development was complete during the teenage years,
recent research has shown that a tremendous amount of change occurs in the brain during
adolescence even up until the early twenties (National Institute of Mental Health, 2011).
Specifically, there is a wave of gray matter production which occurs primarily in the frontal
lobe (National Institute of Mental Health, 2011). The frontal lobe is associated with nu-
merous domains of cognitive function including psychomotor function, planning, reasoning,
judgement, impulse control and memory (Mitrushina, 2005). Since the adolescent and young
adult (AYA) brain is at a developmentally critical period, particularly related to development
of higher level cognitive function, cancer and cancer treatment at this stage may prove to
uniquely affect the brain in survivors of adolescent and young adult cancers. Studies of both
childhood and adult cancer survivors indicate cognitive declines in many different domains
with cancer and cancer treatment, particularly in attention, concentration, working memory,
and executive function (Ahles et al., 2012; Asher & Myers, 2015). However, compared to
adults and children with cancer, considerably less is known about how those diagnosed with
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cancer as an adolescent or young adult (AYA) fare in terms of their cognitive function.
Thus, the purpose of this integrative review was to: 1) summarize the current literature
pertaining to cognitive outcomes of those diagnosed with cancer as an AYA between the ages
of 15 and 24 years; 2) provide a critique of the literature and its relevance to survivors of
AYA cancer; and 3) provide direction for future research. In the context of cancer research,
the AYA age range is variable depending on the country of origin (“What Should the Age
Range Be for AYA Oncology?,” 2011). For example, AYA in the United States is generally
considered to be individuals between the ages of 15 to 39 years (National Cancer Institute
& Lance Armstrong Foundation, 2006); AYAs in Canada are generally considered to be
individuals ages 15 to 29 years (De et al., 2011); AYAs in the United Kingdom are between
ages 13 to 24 years (Teenage Cancer Trust, 2014); and, in Australia between ages 15 to 25
years (CanTeen, 2008). For the purpose of this paper, it was decided to use the term AYA to
mean individuals ages 15 through 24 years because that range represents the intersection of
ranges across the definitions and also captures the important psychological and physiological
changes that occur during adolescence and early young adulthood (“What Should the Age
Range Be for AYA Oncology?,” 2011).
4.2 METHODS
A search of the literature was conducted in PubMed and PsycInfo databases from the earliest
available date through March 30th, 2016. The keywords of “cancer” or “cancer survivor” were
paired with combinations of the terms “cognition”, “cognitive function”, “neurocognitive”,
“neuropsychological”, and “survivorship”. Truncation was used to ensure that both noun
and verb forms of each word were captured. Whenever possible, Medical Subject Heading
(MeSH) terms were used which serve as a kind of thesaurus and are useful in assisting in the
capture of a wider range of relevant literature (U.S. National Library of Medicine, 2015). The
search strategy was restricted to publications written in the English language. To be included
in the review, articles had to meet strict inclusion and exclusion criteria (Figure 1). Inclusion
criteria were: 1) explicitly stating age at diagnosis of sample and inclusion of at least one
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participant diagnosed with cancer between the ages of 15 and 24; and 2) must include at least
one measurement of cognitive function (either patient perception or neurocognitive testing).
Exclusion criteria were: 1) animal studies; 2) studies of participants exclusively diagnosed
with primary brain tumors; and 3) behavioral intervention studies. Studies examining only
participants with primary brain tumors were excluded because there was concern about
the confounding influence of brain tumors on cognitive function independent of treatment.
Intervention studies were excluded, with the exception of cancer treatment studies (e.g.
surgery; radiation; chemotherapy; biologics) since the primary interest is in the effect of
cancer and treatment on cognitive outcomes. Each article was screened by two independent
reviewers using the inclusion and exclusion criteria set forth. If any discrepancies were
encountered, the reviewers discussed and reached an agreement regarding the inclusion of
the article. If agreement could not be reached, further consultation was sought from the
content experts on the team.
Inclusion Criteria Exclusion Criteria 
 English language  At least 1 patient diagnosed with cancer between the ages of 15 and 24  Measurement of cognitive function (either patient perception or neurocognitive function) 
 Studies including only patients with primary brain tumors  Animal studies  Intervention studies (with the exception of therapeutic studies examining surgery, chemotherapy, radiation, or biologics)  
Figure 1: Inclusion and Exclusion Criteria for Integrative Review
4.3 RESULTS
A search of PubMed and PsycInfo databases yielded 641 articles; five additional articles
were identified through review of reference lists of identified articles and citation lists of
known researchers in the field of cancer and cognitive function (Figure 2). Seventeen articles
met the criteria for inclusion in this review (Table 2). The majority of papers were excluded
because participants were not within the AYA age range specified for inclusion in this review.
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The included research was conducted on three continents: North America, Europe, and
Australia. Across all 17 studies, a total of 7,360 cancer survivors are represented. The most
common cancer diagnosis represented in the literature based on sample size was leukemia
which accounted for 31% of all cases. Eleven (64.7%) of the studies included in the review
recruited a convenience sample utilizing a cross-sectional methodology examining cognitive
function at only one time point.
 
Papers excluded after full text assessed (n = 179) 
Iden
tific
atio
n 
Scr
een
ing 
Elig
ibilit
y 
Incl
ude
d 
Papers identified in electronic database searching (n = 641) 
Titles screened (n = 646) Papers excluded (n = 330) 
Abstracts screened (n = 316) Papers excluded (n = 120) 
Full text assessed for eligibility (n = 196) 
Papers included in integrative review (n = 17) 
Papers identified through reference lists (n = 5) 
Figure 2: Integrative review study selection algorithm. The 17 studies that fulfilled the
inclusion/exclusion criteria were selected from the total of 646 possible articles identified.
The process of selecting the 17 articles is displayed.
Four of the studies (Armstrong & Oeffinger, 2013; Krull et al., 2012, 2013; Prasad et
al., 2015) included in the review appear to have been taken from the St. Jude Childhood
Cancer Survivor Study. While this study is extremely important and comprehensive in
terms of measuring longitudinal effects of cancer and treatment in survivors of childhood
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and adolescent cancer, the individuals represented in these studies may not be unique cases.
These four studies included a combined total of 3,159 cancer survivors; it is unclear how
many of these are unique cases.
Two methods of measuring cognitive function were used in the identified studies: patient
perception and neurocognitive testing. Nine studies (52.9%) used only a measure of patient
perception, 6 studies (35.3%) measured cognitive function using a battery of neurocognitive
tests, and 2 studies (11.8%) measured both patient perception and neurocognitive function.
Of those studies that measured patient perception of cognitive function, each study used
either an unvalidated tool or one of five validated questionnaires: the 2-item cognitive func-
tional scale of the European Organization for Research and Treatment of Cancer Quality of
Life Questionnaire (EORTC QLQ-C30); the 6-item Cognitive subscale of the Health Utilities
Index Mark III (HUI3); the 51-item Functional Assessment of Cancer Therapy- Cognitive
(FACT-Cog); the 75-item Behavior Rating Inventory of Executive Function- Adult Version
(BRIEF-A), or the Childhood Cancer Survivor Study Neurocognitive Questionnaire (CCSS-
NCQ).
Studies examining patient perception of cognitive function found that cancer survivors
reported difficulty in domains of memory, motor, and task completion (Alvarnas et al., 2000;
Krull et al., 2012; Prasad et al., 2015). There was a lack of consensus on the trajectory
of patient perception of cognitive function over time: some studies reported that patient’s
perception of cognitive function declined over time (Alvarnas et al., 2000; Hong, Bosco,
Bush, & Berry, 2013), one found no change (Bush, Donaldson, Haberman, Dacanay, & Sul-
livan, 2000), and still others found that cancer survivor’s perception of cognitive function
improved over time (Kiebert, Jonas, & Middleton, 2003). Factors that were associated with
poorer perception of cognitive function included cancer survivors who received particular
chemotherapy agents (Dacarbazine) (Kiebert et al., 2003), patients who had undergone a
stem cell transplant (Hong et al., 2013), and patients who had a previous cancer diagnosis
as compared to those newly diagnosed (Braun, Gupta, & Staren, 2013). Cancer survivors
who had been diagnosed with lymphoma or sarcoma reported fewer neurocognitive difficul-
ties than cancer survivors diagnosed with other types of cancers (Prasad et al., 2015). In
cross-sectional studies, cancer survivors were more likely to report difficulties with cognitive
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function than their healthy counterparts (Pogany et al., 2006; Prasad et al., 2015; Tamnes
et al., 2015; Wright, Galea, & Barr, 2005).
Eight studies used neurocognitive testing to measure cognitive function. Table 3 lists the
various neurocognitive tests that were used to assess each cognitive domain. Across these
8 studies, there were 9 different cognitive domains that study authors reported measuring
using various neurocognitive tests: intelligence, executive function, dexterity, psychomotor
speed, academic achievement, learning and memory, attention, multi-tasking, and language.
On average, each study measuring neurocognitive performance assessed 3 cognitive domains.
Minimum number of domains measured was 1 and maximum number of domains measured
was 5.
In studies measuring intelligence in cancer survivors, two of three studies found that
those who received cranial radiation therapy demonstrated a decline in intelligence over time
(Kumar et al., 1995; Nathan et al., 2013), while another study found no change in intelligence
from pre- to post-stem cell transplant (Hiniker et al., 2014). In studies that used a broad
battery of neurocognitive function, cancer survivors demonstrated impairment in attention,
memory, processing speed, fine motor speed, and cognitive fluency as compared to healthy
controls or normative data (Armstrong et al., 2013; Hiniker et al., 2014; Krull et al., 2012,
2013). One factor that was found to be associated with poorer cognitive function was higher
doses of radiation therapy (Armstrong et al., 2013). Interestingly, two of 6 studies found
that a large portion (between 38-46%) of newly diagnosed cancer patients demonstrated
cognitive impairment prior to receiving chemotherapy (Hiniker et al., 2014; Wefel, Vidrine,
et al., 2011).
To assist in determining relevance of findings to our population of interest, age at di-
agnosis was recorded across all studies (Figure 3). While each study included at least one
individual diagnosed between the ages of 15 and 24 years, only two of the 16 studies in-
cluded a mean or median age that was within our age range of interest. These studies were
reported by Krull, et al (2012), which included Hodgkin’s lymphoma survivors, and Prasad,
et al (2015), which included individuals diagnosed between the ages of 11 and 21 years. The
mean age at diagnosis was 15.1 years and fell at the lower end our age range of interest. Only
one study (Pogany et al., 2006) divided the sample into different groups by age at diagnosis,
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one of which was those diagnosed during 15 and 19 years of age. Still, no study included in
our integrative review included either exclusively those diagnosed during the AYA range or
encompassed the entirety of the AYA age range.
However, three studies included in our review provide some useful information in terms
of cognitive outcomes specifically in those diagnosed with cancer as an AYA. Pogany, et al
(2006) measured perception of cognitive function in cancer survivors. While the mean age at
diagnosis is well under 15 years, in their analysis the sample was split into 5 different groups
based on age at diagnosis and between-group comparisons were made. They found that
approximately 30% of patients diagnosed between ages of 0 and 19 years reported cognitive
impairment. However, using children diagnosed at less than one year of age as the reference
group and adjusting for cancer type, treatment types, gender, and age at survey, patients
diagnosed with cancer between the ages of 15 and 19 years were the only age subgroup that
had higher odds of reporting cognitive impairment than those diagnosed at less than 1 year
of age. This means that those patients diagnosed between 15 and 19 years reported higher
rates of impairment, even after controlling for cancer and treatment types.
Prasad, et al (2015) examined perception of cognitive function in patients diagnosed with
cancer between the ages of 11 and 21 years. The strength of this study is a very large sample
size and many cancer survivors had diagnoses which are particularly relevant to survivors
of AYA cancer. This study well represented three of the six most common AYA cancers:
sarcoma, leukemia, and lymphoma. This is one of only two studies in our review which
included patients who had been diagnosed with sarcomas. Compared to healthy siblings,
cancer survivors reported increased difficulties with task efficiency, emotional regulation, and
memory. Reported difficulty with task efficiency was associated with unemployment. There
were few differences found in perceived cognitive difficulties between those diagnosed at less
than 11 years of age and those diagnosed between 11 and 21 years. However, those with a
diagnosis of lymphoma and sarcoma were less likely to report perceived cognitive difficulties,
than those diagnosed with other types of cancer.
In another study, Krull, et al (2012) conducted both neurocognitive testing and patient
perception of cognitive function. The purpose of this study was to determine if patients
who had received mantle radiation as treatment for Hodgkin’s Lymphoma had decreased
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cognitive function. The sample size for this study was 62 patients with a mean age at
diagnosis of 15.1 years; this was the only study that had a sample mean within our age
range of interest. The results of this study found poorer neurocognitive testing in numerous
domains: sustained attention (p=.004), attention span (p=.01), memory recall [short-term
(p=.001) and long-term (p=.006)], fine motor speed (p¡.001), naming speed (p¡.001), and
cognitive fluency (p=.007). Importantly, neurocognitive performance was associated with the
survivor’s academic and vocational functioning. Survivors reported problems with working
memory, task completion, and fatigue on measures of perceived cognitive function. Poorer
neurocognitive function was not directly associated with mantle field radiation, although it
was associated with cardiac and pulmonary morbidities.
4.4 DISCUSSION
As has been noted in other reviews of cognitive function (Hermelink, 2015; Pullens, Vries, &
Roukema, 2010), the findings from the studies included in this review differ vastly. In stud-
ies with longitudinal designs, some found that cognitive function declined over the course
of cancer treatment, others found it remained unchanged from pre- to post-treatment, and
still others found cognitive impairment in cancer patients before treatment had even been
initiated. Some of the variability was accounted for by chemotherapy regimen given, receipt
of cranial radiation therapy, dose of radiation therapy, or those who had undergone a stem
cell transplant. It is worth noting that two of the eight studies that measured neurocognitive
function prospectively only assessed intelligence, which is known to be a fairly general mea-
surement of neurocognitive function and is not sensitive to more subtle cognitive changes.
Numerous theories have been proposed in an attempt to explain pre-chemotherapy cognitive
changes including effects of the cancer or tumor itself, increased oxidative stress, predisposing
genetic factors or other mechanisms proposed to be involved in treatment-related cognitive
decline (Janelsins, Kesler, Ahles, & Morrow, 2014; Merriman, Von Ah, Miaskowski, & Aouiz-
erat, 2013).
Although each study included in our review included a measure of cognitive function, the
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difference in approach to measuring this concept (either patient perception or neurocognitive
testing) is an important consideration since, although both measurements are informative,
they do not generally align well with one another (Cull et al., 1996; Middleton, Denney,
Lynch, & Parmenter, 2006). Neurocognitive testing is often considered the “gold standard”
in terms of which patients are cognitively impaired. However, the ecological validity of
neurocognitive testing is less understood, particularly in terms of how cognitive function
may impact an individual’s ability to carry out their daily functional activities (Mandy J
Bell, Terhorst, & Bender, 2013). Although research in those diagnosed during adolescence
and young adulthood is limited, numerous studies in other populations of cancer survivors
have found that while cancer survivors may report cognitive difficulty, they still score within
the expected range on neurocognitive testing. The reason for this difference is not entirely
clear, though research has found that patient perception of cognitive function is related to
factors such as depression, anxiety, and fatigue, but is not related to objective performance
on neurocognitive testing (Cull et al., 1996; Middleton et al., 2006). To our knowledge,
research has not been conducted to explore whether there is a relationship between perceived
cognitive function and other downstream effects such as future cognitive decline or whether
it is associated with educational and vocational achievement.
Two of the instruments used to measure patient perception of cognitive function are fairly
minimal in terms of the number of items: The Cognitive functional scale of the EORTC QLQ-
C30 asks one question about memory and another about attention (Fayers et al., 2002);
the cognitive subscale of the HUI3 has 6 different items all asking about some aspect of
memory. While the other two measures of patient perception of cognitive function, BRIEF-A,
FACT-Cog and NCSS-NCQ, are more extensive in terms of the number of items pertaining
to cognitive function, only one study used each of these questionnaires. Thus, although
patient perception of cognitive function was measured in these studies it is by no means a
comprehensive assessment of all domains of cognitive function.
Another important consideration for this age group is the trajectory of cognitive symp-
toms experienced during cancer treatment and into survivorship. Since the majority of the
studies included in our review utilized cross-sectional methodology and did not conduct test-
ing prior to the initiation of treatment, it is difficult to determine the trajectory of cognitive
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symptoms after cancer and treatment. Research conducted in other populations of cancer
survivors have reported short-term cognitive decline that may resolve within a period of time
after treatment is completed (Mar Fan et al., 2005; Wefel, Lenzi, Theriault, Davis, & Meyers,
2004). Many downplay the significance of this short-term cognitive decline as something that
will resolve and have minimal long-term impact. However, in comparison to those diagnosed
at younger and older ages, even short-term cognitive difficulties in AYA may have devastat-
ing long-term effects such as educational and vocational achievement. For instance, children
often receive additional support in primary and secondary school if teachers or support staff
notice that they are struggling or falling behind. And, adults who have completed higher
education or who have obtained a first job have established a career for themselves that,
should short-term cognitive difficulties resolve, can return to work following cancer diagno-
sis and treatment. For those diagnosed during the AYA age, future research is needed to
determine if even short-term cognitive effects may impact survivors in achieving long-term
goals, particularly in light of their stage of life and developmental status. For example, being
diagnosed with cancer during adolescence and experiencing cognitive difficulties (even in the
short-term) may impact an individual’s ability to enroll in higher education or obtain a job.
Delaying or missing these important milestones may have devastating personal and financial
long-term consequences for these individuals.
Across the three different continents where much of the research included in our review
was conducted, the 6 most common cancers seen in the adolescent and young adult popula-
tion are lymphoma, leukemia, germ cell tumor, carcinoma, melanoma, and sarcoma (Table
4). These cancers represent about 80% or more of all the cancer diagnoses seen in this age
group. However, in our review of the literature, many of the AYA cancers were vastly un-
derrepresented in the literature (Figure 4). In particular, melanoma, carcinoma, and germ
cell tumors represent about 40% of all AYA cancer diagnoses; however, these 3 cancer di-
agnoses only accounted for a combined total of 4% of all the diagnoses represented in the
included studies. Thus, findings from the majority of studies included in our review are not
appropriately generalized to the wider AYA oncology population.
There are several limitations to acknowledge for this review. First, ideally, only those
studies looking primarily at the AYA age range or studies with a mean or median within
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our ages of interest would have been included in the review. However, the research was so
limited in this area that inclusion criteria were expanded to allow for studies with an age
range that overlapped our ages of interest so that one or more participants in the study
were diagnosed during the AYA age range; thus, for most studies included in the review it is
uncertain how many participants in each study were diagnosed during the AYA age range.
Second, qualitative research, gray literature such as conference abstracts or dissertations, and
literature written in any language other than English were not reviewed, which might have
limited the number of studies included in our review and the knowledge in this area. Third,
articles which included primary brain tumors were excluded, which limits the generalizability
of the findings from this review. Finally, as is true in other literature reviews, our findings
might be biased due to the fact that studies with statistically significant results are more
likely to be published (Easterbrook, Berlin, Gopalan, & Matthews, 1991; Olson et al., 2002).
4.5 CONCLUSION
Research to date suggests that many cancer survivors report cognitive decline and may
experience a decline in neurocognitive function following cancer diagnosis and treatment.
However, there is a lack of consensus on the best way to measure cognitive function in AYA
patients and it is unclear which domains of cognitive function may be most affected in this
age group. While researchers have called for a uniform battery of neurocognitive tests so that
results can be compared across studies (Noll et al., 2013; Wefel, Vardy, Ahles, & Schagen,
2011), this age group in particular warrants further thought since the ages represented (15
through 24 years of age) includes individuals who may sometimes be given tests appropriate
for childhood and others be given tests appropriate for adults.
Future research is needed to include studies of cognitive function focusing specifically
on those diagnosed during the AYA time frame ensuring adequate representation of com-
mon AYA cancers. In addition, development of a standard battery of instruments to be
used across the entire AYA age range is important in order to compare findings within the
group and across studies. Prospective longitudinal studies that include pretherapy cognitive
21
assessments will be important to determine the trajectory of cognitive symptoms over the
entire course from cancer diagnosis, through treatment and into survivorship. Finally, it
may be valuable to explore implications of cognitive changes (whether short- or long-term)
after cancer and treatment in this vulnerable and understudied population such as the more
distal outcomes of educational achievement and vocational functioning.
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Table 2: Summary of articles included in integrative review
Study, Year (Location) Study Design Patient Group ± Controls (N) 
Age at Diagnosis (years) 
Age at testing (years) 
Domains of cognitive function assessed 
Results Cancers Represented 
Kumar, 1995 (USA) Longitudinal (prior to CSI, 12 and 24 months) 
10 Range: 0.6-16.6 Median: 3.5 1.8-17  Intelligence Nine of 10 survivors treated with Chemo and CSI for CNS relapse demonstrated no decline in intelligence. One patient had frank IQ decline.  
ALL   
Bush, 2000 (USA) prospective longitudinal (1,2,3,4 yrs post-BMT) 
Yr 1: 407-411 Yr 2: 216-217 Yr 3: 115-117 Yr 4: 31-35 
Range: 19-65 Mean: 41.8 20-66 Patient perception Perceived cognitive functioning remained stable throughout the follow-up period. Leukemia, NHL, Breast, Other 
Alvarnas, 2000 (USA) cross-sectional 15 Range: 24-53 Mean: 36.2 24-54 Patient perception Survivors reported decline in neurocognitive function including memory and motor deficits. NHL Kiebert, 2003 (UK) prospective longitudinal RCT (1, 12, 24 wks) 
TMZ: 50  DTIC: 31 Range: 21-88 Mean: 58.6 21-88 Patient perception Over time, cognitive scores improved for TMZ group, but remained unchanged for the DTIC group. 
Melanoma 
Wright, 2005 (Canada) cross-sectional Survivors: 99 HC: 89 Range: 0.3-17 Mean: 5.2  5.1-31.5 Patient perception Significant differences in perceived cognition between survivors and healthy controls. ALL Nathan, 2006 (USA)  
Prospective longitudinal  (0, 12, 24 mos) 
126 Range: 0.3-23.8 Median: 4.7 0.3-23.8  Intelligence Survivors treated with CRT had poorer verbal IQ neurocognitive performance over time, while those treated without CRT improved.  
ALL 
Pogany, 2006 (Canada) cross-sectional Survivors: 2079 HC: 2365 Range: <1-19 Median: 7 5-37 Patient Perception Reports of impairment in dexterity and impaired cognition were more likely in survivors than their peers. 
Leukemia, Lymphoma, CNS/SNS, Retinoblastoma, Renal, Hepatic, Bone, Sarcoma, Germ Cell, Carcinomas Wefel, 2011 (USA) cross-sectional 69 Range: 18.5 - 50.7 Mean: 31.0 
18.5 – 50.7 Attention; Psychomotor Speed; Language; Learning/memory; Executive Function; Motor 
Compared to normative data, approximately 46% of sample was considered neurocognitively impaired before beginning adjuvant chemo.  
NSGCT testicular cancer 
Krull, 2012 (USA) cross-sectional  62 Range: 5.9-19.0 Mean: 15.1 34.4 - 55.4 Intelligence; Attention; Memory; Processing speed; Executive Function; Patient perception 
Compared to normative data, survivors showed declines in attention, memory, fine-motor speed, and cognitive fluency. Survivors self-reported problems with working memory, task completion, and fatigue. 
HL 
Braun, 2013 (USA) cross-sectional new DX: 127 previous DX: 59 Range: 24-85 Mean: 55.1 24-85 Patient perception New DX group tended to have higher perceived cognitive function than those with previous DX Pancreatic Krull, 2013 (USA) cross-sectional 243 Range: 1.0-18.7 Mean: 6.6 Unreported General intelligence; Processing speed; Memory; Attention; Parent-reported 
Survivors had significantly elevated rates of impairment on measures of sustained attention. Parents also reported elevated rates of attention problems. 
ALL 
Hong, 2013 (USA) prospective longitudinal (before/during treatment) 
SCT: 191 Med/Rad: 436 Range: 18-89 Mean: 53.9 18-89 Patient perception Decline in cognitive function found in both groups between Time 1 and Time 2; SCT (medium effect) and MED/RAD (small effect). 
Breast; GI; GU; Gyn; Head and Neck; Leukemia; Lung; Lymphoma; Myeloma; Other 
Armstrong, 2013 (USA) cross-sectional 18 GyRT: 127 24 GyRT: 138 Range: 0-16 Mean: 6.9 Mean: 37.1 Memory; Cognitive status; Intelligence Those who received 24 GyRT had increased impairment in memory and reduced cognitive status, but not the 18GyRT group suggesting a CRT dose-response effect. 
ALL 
Hiniker, 2014 (USA) prospective longitudinal  (pre-SCT, ~4.4 years post-SCT) 
16 Range: 0.9-18 Mean: 5 4.4-21.2 Intelligence; Academic achievement; Working Memory; Motor 
No change in IQ from pre- to post- SCT; 38% of survivors showed deficiencies in processing speed and/or working memory.  
ALL 
Vardy, 2014 (Canada, Australia) 
cross-sectional Local CRC: 291 Met CRC: 66 HC: 72 
Range: 23.1-75.9 Mean: 58.3 Unreported Processing speed;  Learning/memory; Attention 
CRC patients exhibited cognitive impairment in ≥2 domains compared to HC. No significant differences between Local CRC and Met CRC. 
Colorectal cancer 
Tamnes, 2015 (Norway) cross-sectional Survivors: 125 HC: 130 Range: 0.3-16 Mean: 6.2 18.6-46.5 Patient perception ALL survivors reported significantly more problems in executive function than HCs.  ALL Prasad, 2015 (USA) Cross-sectional DX ages 11-21: 2589 DX age < 11: 3603 Siblings: 390 
Range: <6-21 15 - >35 Patient Perception Compared to siblings AeYA reported more difficulty with task efficiency, emotional regulation, and memory. Those diagnosed with lymphoma or sarcoma during AeYA were at decreased risk for self-reporting neurocognitive problems. 
Leukemia, CNS, HL, NHL, Sarcoma 
Abbreviations: BMT bone marrow transplant; NHL non-hodgkin’s lymphoma; NP neuropsychological; ALL acute lymphoblastic leukemia; CRT cranial radiation therapy; RCT randomized clinical trial; SCT stem cell transplant; TMZ temozolomide; DTIC dacarbazine; HC healthy controls; CNS Central Nervous System; SNS Sympathetic Nervous System; NSGCT nonseminomatous germ cell tumors; HL Hodgkin’s Lymphoma; CSI craniospinal irradiation; Med/Rad medical or radiation oncology treatment; GI Gastrointestinal; GU genitourinary; Gyn Gynecologic; CRC colorectal cancer; AeYA adolescent and early young adulthood   
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Table 3: Tests used to measure various cognitive domains across studies
Table 3. Tests used to measure various cognitive domains across studies 
Cognitive Domain Neuropsychological Tests Used 
Intelligence WISC-IV 
WAIS-R 
Wechsler Abbreviated Scale of Intelligence  
Brief Cognitive Status Exam 
Executive Function Trail Making Test Part B 
Controlled Oral Word Test 
WAIS-III Digit Span Backward 
Psychomotor Speed WAIS-R Digit Symbol 
Trailmaking Test Part A 
Dexterity Grooved Pegboard 
Attention, Processing 
Speed, Working 
Memory 
Grooved Pegboard  
Stroop Color-Word Test 
Conners' Continuous Performance Test-II (CPT-II) 
WAIS-III Digit Symbol 
Trail Making Test Part A and B 
WISC-III or WAIS-III Processing speed index 
WISC-III or WAIS-III Freedom from distractibility index 
Trail Making Test Part A 
WAIS-R Digit Span 
WAIS-III Letter-Number Sequencing 
WAIS-III Digit Span Forward 
WMS-III Digit Span 
WMS-III Spatial Span 
Cambridge Neuropsychological Test Automated Battery (CANTAB) 
Learning & Memory Hopkins Verbal Learning Test (HVLT) 
Hopkins Verbal Learning Test-Revised (HVLT-R) 
Brief Visuospatial Memory Test-Revised (BVMT-R) 
Cambridge Neuropsychological Test Automated Battery (CANTAB) 
Wide Range Assessment of Memory and Learning (WRAML2) 
Wechsler Memory Scale 
Language Skills MAE Controlled Oral Word Association 
Multi-Tasking Six Elements Test 
Academic 
Achievement 
Woodcock Johnson Tests of Academic Achievement (WJ-III) 
Patient Reported European Organization for Research & Treatment of Cancer Quality of Life Questionnaire (EORTC  
     QLQ-C30) 
Health Utilities Index Mark III (HUI3) 
Functional Assessment of Cancer Therapy- Cognitive (FACT-Cog) 
Behavior Rating Inventory of Executive Function- Adult Version (BRIEF-A) 
CCSS Neurocognitive Questionnaire (CCSS-NCQ) 
Parent-reported 
Attention 
Conners’ Parent Rating Scale 
 WISC-IV = Wechsler Intelligence Scale for Children – Fourth Edition 
 WAIS-R = Wechsler Adult Intelligence Scale-Revised 
 WAIS-III = Wechsler Adult Intelligence Scale – Third edition 
 WMS-III = Wechsler Memory Scale – Third edition 
 MAE = Multilingual Aphasia Examination 
 CCSS = Childhood Cancer Survivor Study 
  
24
Figure 3. Sample Age Mean and Range for Included Studies Examining Cognitive Function 
The ages of interest are highlighted in gray (ages 15- 24 years). Each line represents one study. The endpoints of the line indicate the 
range of age at diagnosis for that particular study. The hash mark in the middle of each line represent the mean or median of the 
sample, with the height of the hash mark relative to sample size with larger hash marks indicating a larger sample. 
 
*Estimation of mean based on age groupings and sample size. No measure of central tendency reported in this study. 
Figure 3: Sample Age Mean and Range for Included Studies Examining Cognitive Function.
The ages of interest are highlighted in gray (ages 15- 24). Each line represents one study.
The endpoints of the line indicate the range of age at diagnosis for that particular study.
The hash mark in the middle of each line represent the mean or median of the sample, with
the height of the hash mark relative to sample size with larger hash marks indicating a larger
sample.
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Table 4: Distribution of common AYA cancers across the world
          
a(National Cancer Institute, 2015) 
b(Birch et al., 2002) 
c(Australian Institute of Health and Welfare, 2011)  
  United Statesa (15-19 y.o.) United Kingdom
b 
(15-24 y.o.) Australia
c 
(15-29 y.o.) 
Lymphoma 20.7% 25.5% 15.3% Leukemia 13.8% 10.7% 6.2% Germ cell 12.3% 13.8% 13.9% Carcinoma 19.6% 17.1% 25.3% Melanoma 8.4% 25.6% Sarcoma 13% 11.1% 6.3% TOTAL 79.4% 86.6% 92.6% 
 
 
 
 
 
 
 
 
 
 
 
 
 
a(Teenage Cancer Trust, 2014) 
 
Common AYA Cancers (UK dataa, Ages 15-24) 
Lymphoma26%
Leukemia11%
Germ Cell14%
Carcinoma17%
Melanoma8%
Sarcoma11%
Other13%
Cancers Represented in Literature Review Based on Sample Size (N=7,360) 
Lymphoma23%
Leukemia31%Germ Cell2%
Carcinoma1%
Melanoma1%
Sarcoma13%
Other29%
Figure 4: Comparison of Common AYA Cancers to Those Represented in Integrative Review
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5.0 DISSERTATION MANUSCRIPT #3
COGNITIVE AND OCCUPATIONAL FUNCTION IN SURVIVORS OF
ADOLESCENT AND YOUNG ADULT CANCER
5.1 INTRODUCTION
Adolescents with cancer are greatly understudied, particularly in terms of their survivorship
needs. Studying adult survivors of adolescent cancer is tremendously important because
of the developmentally vulnerable time point in which these individuals receive a cancer
diagnosis and treatment. The healthy peers of adolescent survivors are often completing
their high school education and entering college or the workforce, while adolescents with
cancer are undergoing treatment for disease and miss important life milestones (Bellizzi et
al., 2012; D’Agostino, Penney, & Zebrack, 2011). Studies of brain development show that
the brain, especially the frontal lobe, continues to mature and develop into the early twenties
(National Institute of Mental Health, 2011). Cancer and its treatment could affect the typical
neurological and behavioral development of the adolescent patient with cancer and disrupt
the adolescent survivor’s long term employment status as they move into adulthood.
Despite earlier theories that brain development was complete during the teenage years,
recent research has shown that a tremendous amount of change occurs in the brain during
adolescence even into the early twenties (Dahl, 2004). This is an important consideration
since middle and late adolescence is defined as ages 15-21 years (Erikson, 1950; Marshall &
Tanner, 1974; Nelson et al., 2004). New technologies have allowed in-depth research on the
timing and effects of brain development and have altered long-held assumptions about the
timing of brain maturation. A report released by the National Institute of Mental Health
in 2011 outlines several changes that occur in the brain during adolescent development,
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including a surprising finding that the amount of gray matter is highest during adolescence
(National Institute of Mental Health, 2011). The adolescent brain experiences a wave of
gray matter production specifically in the frontal lobe. The frontal lobe is associated with
several domains of cognitive function including psychomotor function, planning, reasoning,
judgment, impulse control and memory. However, there is a lack of research examining the
cognitive changes experienced by adolescents diagnosed with cancer during this vulnerable
time of brain development.
Previous studies of adult survivors of adolescent and young adult (AYA) cancer have
described rates of employment (Dieluweit et al., 2011; Parsons et al., 2012; Tai et al., 2012).
Results of the studies varied, however they generally indicate some level of reduction in
employment status in survivors of AYA cancer compared to healthy controls. Yet, no study to
date has explored occupational function. Occupational function is much more than whether
or not an individual is employed. Occupational function addresses the physical, mental, and
social health, basic competence and occupational virtues that are required by an individual
to perform some form of work (Tengland, 2011). Thus, exploring occupational function
will yield much richer information than simply whether or not an individual is employed
including more information about how they are able to function in occupational roles.
Studies examining the relationship between occupational function (Calvio et al., 2009,
2010; Feuerstein, Hansen, Calvio, Johnson, & Ronquillo, 2007; Hansen, Feuerstein, Calvio,
& Olsen, 2008) and cognitive function in other populations of cancer survivors have been
conducted. A study of breast cancer survivors revealed that the strongest predictors of work
limitations are difficulties in the cognitive domains of memory and executive function (Calvio
et al., 2010). Similarly, a study of brain tumor survivors found that work limitations were
most significantly predicted by memory, executive function, and attention deficits (Calvio et
al., 2009). In addition, a study of adult survivors of childhood non-central nervous system
cancers showed that impaired task efficiency, organization, memory, and behavioral regula-
tion were all significantly associated with lack of employment as an adult (Kadan-Lottick et
al., 2010). The frontal lobe is involved in numerous domains of cognitive function includ-
ing memory and executive function and dysfunction in this part of the brain is associated
with work limitations in other populations of cancer survivors (Calvio et al., 2009, 2010;
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Kadan-Lottick et al., 2010). However, research has not been conducted to explore these
relationships specifically in those diagnosed with cancer as an adolescent.
The aims of this exploratory study are to: 1) describe cognitive function (using ob-
jective and self-report measures) and self-reported ratings of occupational function among
adult survivors of adolescent cancer; and 2) explore differences in cognitive function and oc-
cupational function between adult survivors of adolescent cancer and age- and sex-matched
healthy controls. This study is innovative because it is the first to examine cognitive function
and occupational function in adults who were diagnosed and treated for cancer as adoles-
cents. Since adolescence is such a developmentally-rich time period, elucidating the potential
disruption of a cancer diagnosis and its treatment may lead to better understanding of cog-
nitive and occupational outcomes associated with adolescent cancer. Clearly articulating
the unique features of the young adult survivor of adolescent cancer experience, including
cognitive function and occupational function, will inform and provide direction for the plan-
ning and implementation of interventions to improve survivor outcomes related to the work
experience.
5.2 METHODS
In this study, a descriptive, comparative design was employed to describe cognitive function
and occupational function among adult survivors of adolescent cancer and explore group
differences between adolescent cancer survivors and age- and sex-matched healthy controls
at a single time point. The study was approved by the University of Pittsburgh Institutional
Review Board. Informed consent was obtained for all participants in the study. For this
study, cancer survivors were recruited from February, 2015 until May, 2016 from the Chil-
dren’s Hospital of Pittsburgh of UPMC outpatient oncology clinic. Eligible cancer survivors
who agreed to take part in the study were asked to refer a “healthy friend/sibling” of the
same sex and within 2 years of their age to serve as a control, although this was not a re-
quired component of participating in the study. All testing occurred at a single visit, often
occurring before or after a regularly scheduled check-up at the outpatient clinic.
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5.3 PARTICIPANTS
Inclusion and exclusion criteria. Inclusion criteria for survivors of adolescent cancer
are: 1) cancer diagnosis between the ages of 15 and 21 years (middle or late adolescence); 2)
currently between the ages of 18 and 39 years; 3) two years or more since active treatment for
disease; and 4) able to speak English. Exclusion criteria for cancer survivors are: 1) diagnosis
of neurological condition or mental impairment prior to cancer diagnosis; and 2) under the
age of 18 years. Healthy controls met the same inclusion and exclusion criteria except that
they had no history of cancer. In addition, healthy controls were frequency matched to the
cancer survivors, being of the same sex and within two years of the survivor’s age. Some of
the cancer survivors that were recruited to the study stated that they did not have a healthy
friend or sibling to ask to participate in the study. In this case, they were included in the
study without a healthy control.
5.4 MEASURES
Cognitive function of participants was measured objectively with a battery of neuropsycho-
logical tests appropriate for adolescents and young adults between the ages of 18 and 39
years. The participants were also asked to complete measures of anxiety, depressive symp-
toms, perception of cognitive function, and questions about their work and occupational
function in daily life. Altogether participants completed 15 measures: 10 neuropsychologi-
cal tests, 1 measure of patient perception of cognitive function, 2 measures of occupational
function, and 2 instruments to measure confounding factors.
Demographic and clinical characteristics. All participants completed a demo-
graphic questionnaire which collected information about race, marital status, education,
and employment. Clinical characteristics including medical history and current medications
were collected; these were verified through use of medical records for the group of cancer
survivors. The Intensity of Treatment Rating (ITR-3.0) Scale (Kazak et al., 2012) is used
to classify the intensity of pediatric cancer therapy according to treatment modality and
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stage/risk level for the patient. The ITR assigns an intensity level based on strict and com-
prehensive criteria from 1 (minimally intensive) to 4 (most intensive) by extracting diagnosis,
stage, and treatment data from a patient’s medical record. The ITR-3.0 is a reliable and
valid instrument (Kazak et al., 2012) that facilitates classification of complex diagnoses and
treatment regimens and allows for comparisons to be made across intensity groups (Chil-
dren’s Oncology Group, 2008). Thus, ITR-3.0 is an appropriate instrument for use in this
study population and has been previously used in research studies of AYA cancer patients
(Parsons et al., 2012).
Neuropsychological Tests. A battery of 10 neuropsychological tests assessing a broad
range of cognitive domains was used in the study. The tests were selected for their demon-
strated reliability, validity, and sensitivity to cognitive function, as well as their relevance
to cognitive development in adolescents and young adults. The tests described below are
routinely evaluated in a neuropsychological examination of adolescents.
Digit Vigilance (DV) Test (Lafayette Clinical Repeatable Neuropsychological Test Bat-
tery, 1989) is used as a measure of capacity for sustained attention and visual discrimination
on a repetitious task. Participants are asked to scan 2 pages of numbers and asked to cross
out every appearance of a specified target number as quickly and accurately as they can.
Score is the amount of time needed to complete the task with higher scores indicating poorer
function.
Digit Symbol Substitution (DSS) Test (Wechsler, 1981) is used to assess one’s capacity
for sustained, focused concentration and directed visual shifting and is largely unaffected by
memory or learning. Participants are given a coding key in which numbers are paired with a
unique symbol. For the task, participants are instructed to draw the symbol corresponding
to each number as shown in the key as quickly as they can. Score is the number of symbols
completed correctly in a given amount of time with higher scores indicating better function.
Grooved Peg Board Test (GPBT) (Lafayette Instrument Company, 2002) assesses dex-
terity and psychomotor functioning. The board consists of 25 randomly placed holes and 25
pegs with a key along one side. Pegs must be rotated to match the hole before they can be
inserted. Scoring for this test is the amount of time it takes to insert all pegs into the holes
successfully.
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Stroop Color and Word Test (Golden & Freshwater, 1978) is a measure of executive
function and cognitive inhibition. The test consists of three trials measuring the relative
speed of one’s ability to read the names of colors (Word), naming colors (Color), and naming
colors from words of colors printed with an incongruently colored ink (Color-Word). The
Stroop interference score is the difference between the Color-Word score and the predicted
Color-Word Score based on performance on the Color and Word tests. Higher scores on the
Stroop interference score indicate better function.
Verbal Fluency Test (Spreen & Benton, 1977) is a subtest of the Neurosensory Center
Comprehensive Examination for Aphasia. The test requires participants to say as many
words as possible in 1 minute that begin with the letters F, A, and S (alternating). One point
is given for each unique word spoken by the participant. To successfully retrieve words, the
verbal fluency test requires control of executive function over cognitive processes including
selective attention, mental set shifting, internal response generation, and self-monitoring.
Higher scores indicate better functioning.
Trail Making Test (TMT) A and B (Reitan, 1955) consists of 25 circles distributed
across a sheet of paper for each test. In Test A, the circles are numbered from 1-25 and the
participant is asked to draw lines connecting the numbers in ascending order. In Test B, the
circles include both numbers (1-13) and letters (A-L). Similar to Test A, the participant is
asked to connect the circles in ascending order, but with the additional task of alternating
between letters and numbers (i.e., 1-A-2-B-3-C, etc.). Participants are instructed to draw
lines connecting the circles in order as quickly as possible. The TMT tests assess executive
function, mental flexibility and attention. Scores on the TMT are the amount of time taken
to complete the task with higher scores indicating poorer function.
Wechsler Memory Scale (Wechsler, 2009) is designed to measure a variety of aspects
of memory. For this test the participant is read a short story and asked to recall details
from the story. There is also a delayed recall component that occurs 20-30 minutes after
the immediate recall. The score is the total number of items recalled correctly with higher
scores indicating better function.
Letter Number Sequencing Test (Wechsler, 2008) is part of the Wechsler Intelligence
Scale and is a measure of working memory, the ability to simultaneously organize and recall
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stimuli of different and similar types. In the Letter Number Sequencing Test, the examiner
presents combinations of letters and numbers from 2 to 9. The participant must first repeat
the numbers in the sequence in ascending order, then the letters in alphabetical order. Score
is the number of sequences recalled correctly with higher scores indicating better function.
Rey-Osterrieth Complex Figure Test (ROCF) (Rey & Osterrieth, 1993) assesses visual
perceptual, skills, spatial organization, constructional ability, and visual memory (immediate
and delayed recall). Participants are instructed to carefully copy a figure and then, without
prior warning, to redraw the figure immediately after the figure is removed and again in,
approximately 30 minutes later (delayed recall). Score is based on the number of items
correctly drawn and placed with higher scores indicating better function.
Wisconsin Card Sorting Test (WCST) (Heaton, Chelune, Talley, Kay, & Curtiss, 1993)
is primarily used to assess perseveration and abstract thinking in individuals, but is also con-
sidered a measure of executive function because of its sensitivity to frontal lobe dysfunction.
Administration of the WCST requires use of a deck of stimulus cards. The cards can be
matched by number (1/ 2/ 3/ 4), color (red/ green/ blue/ yellow), or shape (circle/ square/
star/ cross). The participant is shown four stimulus cards at a time and then is asked to
match a card from the deck to one of the stimulus cards, but is not instructed on what rule to
match the cards. The participant will be told “correct” or incorrect” depending on whether
they guess the rule correctly or not. Scoring is based on the number of cards matched cor-
rectly, but also yields a perseveration score from the number of “incorrect” guesses which
would have been “correct” based on the previous rule.
Perceived cognitive function. Patients Assessment of Own Functioning Inventory
(PAOFI) (Chelune, Heaton, & Lehman, 1986) is a self-report measure of cognitive difficul-
ties which has shown correlation with changes in neuropsychological functioning in samples
of cancer patients (Bender et al., 2006, 2008; Pullens, Vries, et al., 2010) and has been shown
to be a reliable and valid instrument (Bell, Terhorst, & Bender, 2013). The PAOFI assesses
perceptions of performance in five different domains of cognitive functioning: memory, exec-
utive function, language, orientation, and sensorimotor ability. Higher scores on the PAOFI
indicate poorer perceived cognitive function.
Anxiety, Fatigue and Depression. Depressive symptoms were measured with the full
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20-item Center for Epidemiological Studies-Depression Scale-Revised [CESD-R] (Radloff,
1977) which has shown good reliability and validity in a sample of cancer patients (Hann,
Winter, & Jacobsen, 1999). Anxiety and fatigue were measured by the Profile of Mood
States-Short Form [POMS-SF] (Curran, Andrykowski, & Studts, 1995) Tension-Anxiety
subscale and Fatigue-Inertia subscale, respectively. The POMS-SF has also demonstrated
good reliability and validity (Curran et al., 1995).
Occupational Function. The Work Limitations Questionnaire (WLQ) (Lerner et al.,
2001) is a 25-item self-report measure of work functioning. The WLQ has shown reliability
and validity for use among several different jobs and chronic health condition groups including
those with cancer (Gordon et al., 2011). The WLQ yields four subscale scores when a
respondent was limited in performing a specific dimension of their job (Time, Physical,
Mental and Interpersonal, and Output) and a total score. Higher scores indicate poorer
function.
Missing Data. In the case of missing item responses on multi-item questionnaires,
unless instructed otherwise by the instrument developer, as long as 80% of items for each
subscale and total score were completed by the participant, we calculated the mean item
response from the available item responses to impute values for the missing items and obtain
subscale and total scores. In the event that less than 80% (or the developer specified amount)
of items had been answered for a particular subscale or sum score, no score was calculated.
5.5 DATA ANALYSIS
Data were first screened for any anomalies (i.e., outliers, normality, multicollinearity, etc.)
by group using descriptive and exploratory analyses. Group-specific standard descriptive
statistics, consistent with a variable’s level of measurement and observed distribution, were
calculated. We performed comparative analyses to explore whether there were any differences
on demographic or clinical characteristics between those cancer survivors who were able to
refer a healthy control and those unable to refer a healthy control. We also explored whether
there were differences on demographic characteristics between the survivors of adolescent
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cancer and healthy control groups. Tests to look for between group differences included
independent sample t-tests for interval and ratio variables (e.g., age, years of education, age
at diagnosis, time since treatment, depressive symptoms, level of fatigue, and intensity of
treatment rating) and chi-square tests of independence or Fisher’s exact test if sparse cells
for nominal variables (sex, race, marital status, clinically significant anxiety symptoms, and
cancer diagnosis). Given the sample size of the study, nonparametric testing using the Mann-
Whitney U-test for interval and ratio scaled variables was used in cases of nonnormality or
if outliers were present.
For aim 1, simple descriptive statistics including means and standard deviations were cal-
culated for each subscale and total score in both the adolescent cancer survivor and healthy
control groups. The confidence interval of the mean (95%) was calculated and reported for
the survivor of adolescent cancer group. For aim 2, given the small sample size we focused
on the estimation of effect sizes with confidence intervals rather than hypothesis testing.
Additionally, one-way multivariate analysis of variance (MANOVA) with test-specific inde-
pendent samples t-tests were conducted for cognitive and occupational function between
the survivor and healthy control groups. Effect sizes as the standardized mean difference
(Cohen’s d) with 95% confidence intervals were calculated for each neuropsychological test,
subscale, and total score. Interpretation of effect sizes of Cohen’s d were guided by general
ranges put forth in the field of neuropsychology where an effect size of 0.20-0.49 is considered
a small effect, 0.50-0.79 is considered a medium effect, and 0.80 and greater is considered
a large effect (Zakzanis, 2001). Separate MANOVA’s were performed for the sets of tests
for each domain of cognitive function (attention, memory, and executive function), except
for the domain of psychomotor speed where an independent t-test was used since there was
only one primary score for this domain. Additionally, we explored the correlation of per-
ceived cognitive function with depressive symptoms, anxiety, and fatigue using Spearman’s
rho since these factors have been shown to be correlated to perceived cognitive function in
other populations of cancer survivors (Merriman et al., 2015; Vardy, Wefel, Ahles, Tannock,
& Schagen, 2008), yet has not been explored in survivors of adolescent cancer. Assumptions
of MANOVA (independence of observations, homogeneity of group variance-covariance ma-
trices, no multicollinearity among dependent variables, multivariate normality, and linear
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relationship between pairs of dependent variables with each level of categorical independent
variable, and no univariate or multivariate outliers) (Nimon, 2012) and independent t-test
(i.e., normality, linearity, sphericity, and homogeneity of regression slopes) (Pallant, 2013)
were met for dependent variables in the model. There were no univariate outliers in our
study, but there was one multivariate outlier, a cancer survivor who demonstrated an un-
usual pattern in performance on neuropsychological measures of attention. Analyses were
performed with and without this individual. The analyses which included the multivariate
outlier did not change the conclusions drawn, thus we opted to use the entire sample in our
analysis.
5.6 RESULTS
Statistically significant between group differences were not found in regards to cancer sur-
vivors who were able to refer a healthy control and those unable to refer a health control with
respect to demographic factors and disease and treatment characteristics. Thus, we opted to
use the entire sample for our study. Demographic and clinical characteristics of the sample
are shown in Table 5. Twenty-three cancer survivors and fourteen healthy controls were
included in our analysis. Fifty-nine percent (n = 14) of the survivors included in our study
were able to identify a healthy age- and gender-matched friend to serve as a healthy control.
Cancer survivors were approximately 23 years of age and had some (14.7 mean years) college
education. The majority of participants were Caucasian (n = 21, 91.3%), male (n = 16,
69.6%), and had never married (n = 20, 87,0%). The mean age at diagnosis for the survivor
group was 17.4 years and cancer treatment lasted about 1 year, on average. The most com-
mon cancer diagnosis was Hodgkin’s Lymphoma (n = 10, 43.4%). There were no differences
between the cancer survivor and healthy control groups except for levels of anxiety. Can-
cer survivors had significantly higher anxiety scores than the healthy controls (p = .049);
however, the mean level of anxiety reported by survivors was still within the normal range
based on population normative data. Since research has shown that self-reports of anxiety
symptoms in the absence of clinically significant anxiety is not known to affect cognitive
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performance (Waldstein, Ryan, Jennings, Muldoon, & Manuck, 1997), level of anxiety was
recoded as a dichotomous variable (clinically significant anxiety or not clinically significant
anxiety). There were no differences in the number of people in each group reporting clini-
cally significant levels of anxiety (t-score greater than or equal to 60) (Curran et al., 1995),
p = 0.275. Thus, anxiety was not included as a covariate in the model.
Table 5: Baseline characteristics of survivors of adolescent cancer and healthy control groups
Table 5. Baseline characteristics of survivors of adolescent cancer and healthy control groups 
Characteristic Survivors of AYA 
Cancer 
n=23  
Healthy Control 
n=14 
Test 
Statistic 
p-value 
 Mean ± SD 
Median (IQR) 
Mean ± SD 
Median (IQR) 
  
Age (years) 23.8 ± 4.0 
22.6 (5.0) 
22.9 ± 3.8 
21.7 (3.1) 
t=0.64 
UMW=133.0 
.526 
.394 
Education (years) 14.7 ± 2.4 
15.0 (5.0) 
14.7 ± 2.5 
14.0 (4.0) 
t=0.03 
UMW=152.5 
.976 
.793 
Disease and Treatment Factors     
   Age at Diagnosis (years) 17.4 ± 1.9 NA -- -- 
   Length of Treatment (years) 1.2 ± 1.4 NA -- -- 
Mood     
   Depressive Symptoms 11.7 ± 11.9 
7.0 (14.0) 
9.5 ± 8.9 
7.1 (13.0) 
t=0.62 
UMW=149.0 
.538 
.722 
   Anxiety (T score) 48.9 ± 11.5 
49.0 (20.0) 
41.7 ± 7.5 
39.5 (9.0) 
t=2.04 
UMW=98.0 
.049 
.049 
   Fatigue (T score) 46.3 ± 10.2 
44.0 (19.0) 
43.3 ± 6.7 
42.0 (9.0) 
t=0.94 
UMW=135.5 
.354 
.429 
 Percent (n) Percent (n)   
Sex (Male) 69.6 (16) 64.3 (9) -- 1.000FE 
Marital Status (Never Married) 87.0 (20) 85.7 (12) -- 1.000FE 
Race (Caucasian) 91.3 (21) 85.7 (12) -- 0.625FE 
Hispanic Descent (No) 95.7 (22) 78.6 (11) -- 0.142FE 
Identified a Healthy Control (Yes) 60.8 (14) NA -- -- 
Cancer Diagnosis     
   Acute Lymphoblastic Leukemia 17.4 (4) NA -- -- 
   Acute Myelocytic Leukemia 4.3 (1) NA -- -- 
   Osteosarcoma 8.7 (2) NA -- -- 
   Chondrosarcoma 4.3 (1) NA -- -- 
   Ewing’s Sarcoma 8.7 (2) NA -- -- 
   Germ Cell Tumor 8.7 (2) NA -- -- 
   Hodgkin’s Lymphoma 43.4 (10) NA -- -- 
   Non-Hodgkin’s Lymphoma 4.3 (1) NA -- -- 
SD Standard Deviation, IQR Interquartile Range, MW Mann Whitney U Test; NA Not Applicable;  
FE Fisher’s Exact
The results for the comparisons between survivors of AYA cancer and healthy controls for
cognitive function are summarized in Table 6. Although no statistically significant differences
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were found based on multivariate and univariate analysis of variance, effects that were seen
suggest poorer cognitive function in cancer survivors than in healthy controls. In addition,
effect size calculation indicated several cognitive domains demonstrating small or medium
sized effects for one or more neuropsychological tests or subscale scores. The effect size
for the digit vigilance test (d = 0.396) and the Stroop interference score (d = −0.226)
fell into Cohen’s (1988) range for a small effect. Small or medium effect sizes were found
for all perceived cognitive function subscales except the sensory perceptual domain. Total
perceived cognitive function scores for cancer survivors also exhibited a small to medium
effect (d = 0.441) indicating that survivors of adolescent cancer (M = 32.78, SD = 23.02)
reported greater difficulty with overall cognitive functioning as compared to healthy controls
(M = 23.71, SD = 15.54). A follow-up analysis found that, for both cancer survivors
and healthy controls, poorer perceived cognitive function in each subscale (except the Use
of Hands) and total perceived cognitive function were correlated to increases in level of
depressive symptoms, anxiety and fatigue and were found to be significant at the .05 level.
The results for the comparisons between survivors of AYA cancer and healthy controls
for occupational function are summarized in Table 7. For work limitations, no statistically
significant differences were found for participants who were working comparing between
survivors of adolescent cancer and healthy controls. Effect size estimation, however, revealed
a small to medium effect in reported work output (d = 0.430) indicating that survivors of
adolescent cancer (M = 21.66, SD = 29.98) who were working reported worse work output
than healthy controls (M = 10.71, SD = 14.92) who were working.
Finally, the correlations between perceived cognitive function and depressive symptoms,
anxiety, and fatigue can be found in Table 8. We conducted a follow-up analysis and found
that, for both cancer survivors and healthy controls, poorer perceived cognitive function
in each subscale (except the Use of Hands) and total perceived cognitive function were
correlated to increases in level of depressive symptoms, anxiety and fatigue and were found
to be significant at the .05 level.
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5.7 DISCUSSION
The purpose of this study was to describe cognitive and occupational function in survivors
of adolescent cancer and explore differences in cognitive and occupational function between
survivors of adolescent cancer and healthy controls. We did not find statistically significant
differences in cognitive or occupational function between cancer survivors and healthy con-
trols. However, we did detect two small effect sizes for neuropsychological performance and
several small and medium effect sizes in perceived cognitive function. Finally, we found a
small to medium effect size in reported work output in the cancer survivor group.
While statistically significant differences between survivors of adolescent cancer and
healthy controls were not found, this may have been due, in part, to a limited sample size, or
the inability of the chosen neuropsychological measurements to detect subtler cognitive dif-
ferences between groups. Effect size measurements of neuropsychological tests using Cohen’s
d, suggest that survivors of adolescent cancer may experience difficulty in some aspects of
memory and executive function. Furthermore, the digit vigilance test and Stroop test may
be sensitive tests in detecting between group differences in survivors of adolescent cancer and
healthy controls. This is consistent with findings from other studies which suggest that both
the digit vigilance and Stroop tests demonstrate excellent sensitivity to more subtle changes
in cognitive function. The Stroop test has been found to be sensitive in detecting prefrontal
dysfunction (Homack & Riccio, 2004) and the Digit Vigilance Test demonstrates excellent
sensitivity in detecting frontal lobe dysfunction (Lafayette Clinical Repeatable Neuropsycho-
logical Test Battery, 1989). However, it must be restated that this is the first study designed
to explicitly measure cognitive function in survivors of adolescent cancer and thus we are
unable to directly to compare with other studies findings in this population.
Survivors of adolescent cancer reported greater perceived cognitive difficulty including
poorer memory, language and communication skills, higher level cognitive and intellectual
function, and total perceived cognitive function than their gender- and age-matched healthy
counterparts. These findings are consistent with others who have found that cancer survivors
report poorer perceived cognitive function than healthy controls even in the absence of worse
neuropsychological function (Mehnert et al., 2007; J. L. Vardy et al., 2008). Similar to other
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research in perceived cognitive function in cancer survivors, we found an association between
perceived cognitive function and levels of anxiety, depressive symptoms, and fatigue (Mer-
riman et al., 2015; J. L. Vardy et al., 2008). However, it is uncertain whether symptoms of
anxiety, depression, and fatigue contribute to poorer perceived cognitive function or whether
they may be the result of subtle cognitive difficulties that may go undetected in measures of
neuropsychological function.
It has been theorized that greater perceived cognitive difficulty may relate to compen-
satory mechanisms in the brain even in the absence of impaired neuropsychological function
(Reuter-Lorenz & Cimprich, 2013; Von Ah & Tallman, 2015). For instance, research using
functional MRI’s (fMRI’s) in other populations of cancer survivors have shown that although
neuropsychological performance may not be impaired, the alterations in activation patterns
in the brain suggest a compensatory mechanism whereby greater effort and mental processes
are required to perform similarly to heathy controls (Cimprich et al., 2010; R. J. Fergu-
son, McDonald, Saykin, & Ahles, 2007; McDonald, Conroy, Ahles, West, & Saykin, 2012).
Future research is needed to investigate whether or not perceived cognitive difficulties may
align with mechanisms of compensation in the brain and whether or not the deficits align
with education or work outcomes.
Survivors of adolescent cancer in our sample were not less likely to be employed or work
part-time than their healthy counterparts; however, survivors of adolescent cancer did report
reduced work quality and quantity as compared to healthy controls (Lerner et al., 2001).
While numerous studies have examined the concept of “return to work” following cancer
diagnosis, survivors of adolescent cancer warrant further investigation since these individuals
often are not employed at the time of cancer diagnosis and treatment. For survivors of
adolescent cancer, there is the additional factor of pursuing higher education or training and
establishing a career and entering the workforce after cancer diagnosis and treatment. To our
knowledge, the concept of assisting survivors of adolescent cancer in entering the workforce
has not been previously explored. Whether cancer survivors only perceive reduced work
output or in fact have reduced quantity and quality of work should be further explored
since this may have great impact on their ability to maintain employment and could have
vast financial implications for this population. Future research will be important to explore
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factors that contribute to poorer work output with consideration to both qualitative and
quantitative methods. Investigation into how to best support this vulnerable population in
achieving professional goals and optimal occupational functioning is of particular importance
given their life stage.
5.7.1 Strengths and Limitations
There are several limitations to acknowledge in our study. First, this study used a cross-
sectional design so we were unable to examine whether there were changes in cognitive
function over time. Future studies should include a longitudinal design to permit examina-
tion of changes in cognitive function including a testing performed pre-treatment. Second,
our limited and unequal sample sizes did not provide adequate power to focus on hypothesis
testing and may have contributed to the lack of statistically significant differences observed.
The small sample sizes also prevented more complex analyses including adequate power to
investigate the relationship between cognitive and occupational function. Third, the neu-
ropsychological measures used in this study did not provide a comprehensive assessment of
all domains of cognitive function and may not have been sensitive to subtle differences be-
tween groups. The neuropsychological battery was limited to 10 tests assessing four domains
of cognitive function so as to limit subject burden and fatigue. However, a more extensive
neuropsychological battery may have detected statistically significant differences between
the groups that we were unable to detect.
The strengths of this study include the use of a neuropsychological battery specifically
chosen to measure aspects of cognitive function that are developing during adolescence. Our
sample was composed exclusively of individuals diagnosed with cancer during adolescence
and included a matched control group of healthy individuals. To our knowledge, this is
the first study specifically designed to explore cognitive function in survivors of adolescent
cancer.
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5.7.2 Conclusions
Findings suggest that survivors of adolescent cancer may or may not exhibit poorer perfor-
mance on objective measures of cognitive function. However, survivors of adolescent cancer
consistently report poorer perceived cognitive function than their healthy counterparts. In
addition, there were no statistically significant differences in the rate or level of employment
between adolescent cancer survivors and healthy controls, however adolescent cancer sur-
vivors reported more difficulty with work output compared to their healthy counterparts.
Future, longitudinal studies are needed that include a larger sample of survivors of AYA
cancer to elucidate who is at risk for cognitive difficulties and difficulty with work output.
Clearly understanding the cognitive and occupational problems associated with disease and
treatment will inform development of interventions to assist survivors in achieving optimal
functioning.
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Table 6: Cognitive function in survivors of adolescent cancer compared to healthy controls
Table 6. Cognitive function in survivors of adolescent cancer compared to healthy controls 
 Higher scores indicate better performance, except where noted. 
C.I. Confidence Interval 
† Higher scores indicate poorer performance. 
FMV = Multivariate F statistic 
FUV = Univariate F statistic 
*Small effect size 
**Medium effect size 
 
  
Test Cancer Survivors 
Mean ± SD 
[95% C.I.] 
n=23 
Healthy Controls 
Mean ± SD 
n=14 
Test statistic 
p-value Cohen’s d 
[95% C.I.] 
Attention   FMV = 0.671 
p = .518 
 
   Digit Vigilance (sec)† 409.13 ± 100.72 
[365.58, 452.69] 
370.91 ± 88.95 FUV = 1.365 
p = .251 
d = 0.396* 
[-0.28, 1.07] 
   Digit Symbol, 90-sec total  
     (number correct) 
80.52 ± 14.54 
[74.24, 86.81] 
82.79 ± 15.85 FUV = 0.197 
p = .660 
d = -0.151 
[-0.82, 0.51] 
Memory   FMV = 0.343 
p = .883 
 
   Letter Number Sequencing  
     (number correct) 
11.26 ± 3.19 
[9.88, 12.64] 
11.07 ± 3.22 FUV = 0.199 
p = .658 
d = 0.059 
[-0.61, 0.72] 
   Rey Figure, Immediate (scaled score) 22.48 ± 6.47 
[19.68, 25.27] 
21.64 ± 6.68 FUV = 0.564 
p =.564 
d = 0.128 
[-0.54, 0.79] 
   Rey Figure, Delayed (scaled score) 22.09 ± 6.63 
[19.22, 24.95] 
20.82 ± 6.50 FUV = 0.639 
p = .429 
d = 0.193 
[-0.47, 0.86] 
   Stories B & C, Immediate (no. correct) 25.61 ± 5.71 
[23.14, 28.08] 
25.64 ± 5.34 FUV = 0.013 
p = .909 
d = -0.005 
[-0.670, 0.659] 
   Stories B & C, Delayed 
      (number correct) 
22.70 ± 5.64 
[20.25, 25.14] 
23.46 ± 5.09 FUV = 0.164 
p = .688 
 d = -0.140 
[-0.80, 0.53] 
Executive Function   FMV = 0.163 
p = .956 
 
   Stroop Interference (scaled score) 3.96 ± 8.08 
[0.46, 7.45] 
5.86 ± 8.97 FUV = 0.443 
p = .510 
d = -0.226* 
[-0.89, 0.44] 
   Trail Making, Part B (seconds)† 69.21 ± 23.13 
[59.21, 79.22] 
71.50 ± 31.81 FUV = 0.064 
p = .802 
d = -0.086 
[-0.75, 0.58] 
   Verbal Fluency, FAS 
     (number correct) 
37.70 ± 11.54 
[32.70, 42.69] 
38.50 ± 11.23 FUV = 0.043 
p = .837 
d = -0.070 
[-0.73, 0.59] 
   Wisconsin Card Sorting Test Perseverative  
     Errors (number of errors)† 
9.09 ± 5.52 
[6.70, 11.47] 
9.86 ± 7.12 FUV = 0.136 
p = .715 
d = -0.125 
[-0.79, 0.54] 
Psychomotor Speed     
   Grooved Pegboard, Dominant hand  
     (seconds)† 
69.93 ± 17.39 
[62.41, 77.45] 
67.33 ± 14.62 t = 0.461 
p = .648 
d = 0.158 
[-0.51, 0.82] 
Patient Perception   FMV = 1.514 
p = .215 
 
   Memory† 
 
14.96 ± 9.35 
[10.91, 19.00] 
10.00 ± 6.04 FUV = 4.191 
p = .048 
d = 0.599** 
[-0.08, 1.28] 
   Language and Communication† 
 
7.91 ± 5.57 
[5.51, 10.32] 
4.85 ± 4.06 FUV = 3.020 
p = .091 
d = 0.605** 
[-0.07, 1.28] 
   Use of Hands† 1.00 ± 1.31 
[0.43, 1.57] 
1.79 ± 1.53 FUV = 1.695 
p = .202 
d = -0.566** 
[-1.24, 0.11] 
   Sensory Perceptual† 1.22 ± 1.86 
[0.41, 2.02] 
1.29 ± 2.02 FUV =0.233 
p = .632 
d = -0.036 
[-0.70, 0.63] 
   Higher Level Cognitive and Intellectual  
     Function† 
7.70 ± 7.42 
[4.49, 10.90] 
5.79 ± 6.55 FUV = 1.894 
p = .178 
d = 0.269* 
[-0.40, 0.94] 
   Total† 32.78 ± 23.02 
[22.83, 42.74] 
23.71 ± 15.54 t = 1.301 
p = .202 
d = 0.441* 
[-0.23, 1.11] 
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Table 7: Occupational function in survivors of adolescent cancer compared to healthy controls    
C.I. Confidence Interval FMV = Multivariate F statistic FUV = Univariate F statistic *Small effect size an=18  
Occupational Factors Cancer Survivors n (%) n=23 
Healthy Controls n (%) n=14   Work Status        Full-time student, not working 4 (17.4%) 3 (21.4%)      Student and part-time work 5 (21.7%) 4 (28.6%)      Student and full-time work 1 (4.3%) 0 (0.0%)      Part-time work only 3 (13.0%) 0 (0.0%)      Full-time work only 10 (43.4%) 7 (50%)    Mean ± SD n=19 [95% C.I.] 
Mean ± SD n=11 Test Statistic p-value Cohen’s d [95% C.I.] 
Aspects of Occupational Function in participants who are employed   FMV = 1.877 p = .147     Time 21.31 ± 31.04 [7.35, 35.27] 21.36 ± 20.50 FUV = 0.240 p = 0.628 d = -0.002 [-0.74, 0.74]    Physical 8.03 ± 11.88a [2.54, 13.52] 13.03 ± 20.91 FUV = 0.680 p = .417 d = -0.316 [-1.07, 0.44]    Mental-Interpersonal 24.43 ± 27.93 [11.87, 36.99] 22.70 ± 17.33 FUV=0.101 p =.753 d = 0.070 [-0.67, 0.81]    Output 20.53 ± 28.91 [7.53, 33.53] 11.36 ± 15.67 FUV = 0.384 p = .541 d = 0.367* [-0.38, 1.12]    Total 4.50 ± 5.28a [2.13, 6.87] 4.67 ± 4.34 t = -0.090 p = .929 d = -0.034 [-0.78, 0.72] 
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Table 8: Correlation between perceived cognitive function and depressive symptoms, anxiety,
and fatigueTable 8. Correlation between perceived cognitive function and depressive symptoms, anxiety, 
and fatigue 
PAOFI Score 
Depressive 
symptoms 
(n=36) 
Anxiety 
(n=36) 
Fatigue 
(n=36) 
Memory 
     Spearman’s rho 
     p 
 
.528 
.001 
 
.378 
.023 
 
.339 
.043 
Language & Communication 
     Spearman’s rho 
     p 
 
.652 
<.001 
 
.437 
.008 
 
.413 
.012 
Use of Hands 
     Spearman’s rho 
     p 
 
.315 
.062 
 
.293 
.083 
 
.200 
.242 
Sensory Perceptual  
     Spearman’s rho 
     p 
 
.574 
<.001 
 
.510 
.001 
 
.384 
.021 
Higher level Cognitive and Intellectual Function 
     Spearman’s rho 
     p 
 
.769 
<.001 
 
.509 
.002 
 
.456 
.005 
Total 
     Spearman’s rho 
     p 
 
.727 
<.001 
 
.513 
.001 
 
.480 
.003 
PAOFI = Patient Assessment of Own Functioning Inventory  
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6.0 SUMMARY OF DISSERTATION FINDINGS
This dissertation project consists of 3 complementary studies to address several gaps in the
scientific literature on cognitive and occupational function in cancer survivors. Findings are
documented in the following three manuscripts:
Manuscript #1: The association between pre-treatment occupational skill level and
mood and symptom burden in early-stage, postmenopausal breast cancer survivors during
the first year of anastrozole therapy;
Manuscript #2: Cognitive function in survivors of adolescent and young adult cancer:
An integrative review and literature critique; and
Manuscript #3: Cognitive and occupational function in survivors of adolescent cancer.
Although each of these three manuscripts had a distinct purpose, viewing the studies
together reveals several themes. First, this dissertation explored the relationship
between cancer and occupational function. Occupational factors are an important
consideration in cancer survivors both during treatment and in long-term survivors. Un-
derstanding the occupation in which cancer survivors are employed at diagnosis may help
to predict the trajectory of symptom burden over time. This association was explored in
manuscript 1, which revealed that breast cancer survivors employed at lower skill levels
experienced greater overall symptom burden as well as significantly worse musculoskeletal,
vasomotor, and gastrointestinal symptoms than those employed at the higher skill level.
Findings of manuscript 3 suggest that survivors of adolescent cancer reported poorer work
output than their healthy counterparts without a history of cancer. Taken together, these
findings affirm that assessing occupational factors of cancer survivors may have implications
for both symptom management as well as occupational counseling to assist cancer survivors
in finding and maintaining employment.
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This dissertation also explored the relationship between cancer and cogni-
tive function, with particular emphasis on the paucity of research that has been
done in those diagnosed during adolescent and young adulthood. The integrative
review (manuscript 2) demonstrated that while a good deal of work has been done to ex-
plore cognitive function in cancer survivors more broadly, very little research has been done
to explore cognitive function in those diagnosed during adolescence and young adulthood.
No study to date has focused exclusively on measuring cognitive outcomes in survivors of
adolescent cancer. To our knowledge, this dissertation contains the first study conducted to
explore cognitive function specifically in those diagnosed during adolescence (manuscript 3).
We found that survivors of adolescent cancer perceived poorer cognitive function than their
peers without a history of cancer, however we found no significant measurable differences
in objective measures of neuropsychological function. However, our sample size was small
and future studies are needed to examine the cognitive outcomes in this group of vulnerable
cancer survivors.
In conclusion, this dissertation provides an overview of the relationship between work
and cancer and cognitive function and cancer, with particular emphasis on the population
of cancer survivors diagnosed during adolescence and young adulthood. Knowledge ob-
tained from this dissertation work suggests future research studies are needed.
In particular,
1. Exploration of the relationship between cognitive function and occupational function in
cancer survivors.
2. Descriptive studies using a larger sample and longitudinal study design are needed to
explore cognitive function in survivors of adolescent and young adult cancer.
3. Descriptive studies are needed to explore correlates of perceived cognitive function such
as association with compensatory mechanisms in the brain, even in the absence of altered
performance on neuropsychological tests.
4. Future intervention research to promote optimal occupational function in cancer sur-
vivors should test theory-driven strategies to assist cancer survivors in finding and main-
taining employment. While many studies have focused on the concept of “return-to-
work” in cancer survivors, particular considerations are needed to meet the unique needs
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of cancer survivors who have not yet entered the work force when confronted with a
cancer diagnosis.
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APPENDIX A
PRELIMINARY WORK MANUSCRIPT #1: WORK PRODUCTIVITY
AND NEUROPSYCHOLOGICAL FUNCTION IN PERSONS WITH SKULL
BASE TUMORS
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The version of record Nugent BD, Weimer J, Choi CJ, et al. Work productivity and
neuropsychological function in persons with skull base tumors. Neuro-Oncology Practice
2014;1(3):106-113. doi:10.1093/nop/npu015 is available online at: http://nop.oxfordjournals.
org/cgi/content/full/npu015?ijkey=egewQicYRUErDZR&keytype=ref
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Work productivity and neuropsychological function in persons
with skull base tumors
Bethany D. Nugent, Jason Weimer, Chienwen J. Choi, Cathy J. Bradley, Catherine M. Bender, Christopher M. Ryan,
Paul Gardner, and Paula R. Sherwood
University of Pittsburgh School of Nursing, Pittsburgh, Pennsylvania (B.D.N., J.W., C.J.C., C.M.B., P.R.S.); Virginia Commonwealth University
Department of Healthcare Policy and Research, Richmond, Virginia (C.J.B.); University of Pittsburgh Department of Psychology, Pittsburgh,
Pennsylvania (C.M.R.); University of Pittsburgh Department of Neurological Surgery, Pittsburgh, Pennsylvania (P.G)
Corresponding Author: Bethany D. Nugent, BSN, RN, School of Nursing, University of Pittsburgh, 415 Victoria Bldg., 3500 Victoria St. Pittsburgh, PA 15213
(bdt10@pitt.edu).
Background. Skull base tumors comprise many common benign brain tumors. Treatment has advanced, allowing many survivors to
return to work. However, literature is limited about the neuropsychological status of these patients prior to treatment. Literature per-
taining to the relationship between neuropsychological functioning and occupational ability prior to surgical intervention is even more
limited. The purpose of this analysis was to evaluate the impact of neuropsychological function on work productivity in persons with
skull base tumors prior to resection.
Methods. Neuropsychological function and work productivity were assessed in adults newly diagnosed with skull base tumors (n¼ 45)
prior to surgical intervention. Univariate analyses identified potential predictors of work limitations; variables with P, .10 were ana-
lyzed using multivariate regression analyses controlled for age, sex, tumor type, and education.
Results. Poorer mental attention and flexibility (MF) and higher depressive symptoms (DS) were significantly associated with poor time
management at work (MF: b¼ -0.59, P¼ .01; DS: b¼ 3.42, P, .01; R2¼ 0.54). Difficulty meeting physical work demands was signifi-
cantly associated with poorer visuospatial ability (VA) and higher depressive symptoms (VA: b¼23.30, P¼ .05; DS: b¼ 2.29, P, .01;
R2¼ 0.29). Lower learning and memory scores (LM) and higher depressive symptoms were significantly associated with difficulty
meeting mental-interpersonal work demands (LM: b¼23.39, P¼ .04; DS: b¼ 3.25, P, .01; R2¼ 0.47) and overall health-related
loss of work productivity (LM: b¼20.72, P¼ .05; DS: b¼ 0.659, P, .001; R2¼ 0.43).
Conclusion. Domains of neuropsychological function that predicted work productivity were identified. Future research should examine
neuropsychological function, depressive symptoms, and work productivity across the care trajectory from diagnosis through long-term
survivorship.
Keywords: cognitive function, neuropsychological function, occupational function, skull base tumors, work ability.
Since the 1970s, the incidence of benign brain tumors has been
on the rise, due in part to improved technology and ability to
detect neoplasms.1,2 According to the Central Brain Tumor Regis-
try of the United States [CBTRUS], 142 000 new cases of benign
intracranial tumors are diagnosed each year; 48% of all intracra-
nial tumors are benign.1 While there are several different types of
benign brain tumors, some of the most common are skull base
tumors including adenomas, meningiomas, and Rathke cleft
cysts.3–7 The skull base includes the bones that form the bottom
of the head and the back of the eye socket.
The focus in brain tumors has centered on the diagnosis and
treatment of malignant tumors. There has been growing
recognition, however, that benign intracranial tumors, including
skull base tumors, can impose significant societal costs related
to medical care, case fatality, and lost productivity.1 In contrast
to most other brain and nervous system tumors, the diagnosis
of a skull base tumor does not automatically qualify an individual
for disability under the United States Social Security Act8 and thus
may not allow the individual to quit work or qualify for disability.
Yet, even benign brain tumors have the ability to cause altered
physical and neuropsychological function.9–12However, theman-
ner in which these alterations affect a person’s ability to fulfill nor-
mal obligations, such as meeting occupational demands, is
unknown. This potential for work disruption in particular has
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significant societal and personal implications that are not known.
The purpose of this analysis was to examine the relationship be-
tween neuropsychological function and work productivity in indi-
viduals with a skull base tumor prior to any treatment or
resection.
Background
Many skull base tumors are considered to be benign. If the tumor
does not grow, is seemingly asymptomatic, or produces only min-
imal symptoms, the recommended treatment may be to contin-
ue careful monitoring (watchful waiting) in an attempt to avoid
overly aggressive treatment that may expose the patient to
more risk than the expected benefit.13,14 The risk/benefit of non-
surgical management of skull base tumors is limited, especially
as it impacts daily activities. However, Van Nieuwenhuizen,
et al12 found that patients with low-grade meningiomas under-
going the watchful waiting approach had lower psychomotor
speed and working memory capacity.
One of the main difficulties in assessing the impact of symp-
toms on persons’ lives is that alterations in neuropsychological
function and the accompanying symptoms are common but
often “silent” because they can be quite subtle and develop grad-
ually. Alterations in neuropsychological function may not be as
readily recognized as physical dysfunction, yet it can still have a
large impact on patients’ ability to continue societal, familial,
and occupational roles. Research has shown an association be-
tween impaired neuropsychological function and poor work per-
formance and employability in other patient populations.15–18
There is sparse literature regarding the impact of neuropsycho-
logical function on occupational obligations in persons with any
type of primary brain tumor. Teixidor, et al19 found preoperatively
that patients with a tumor in the language center of the brain
scored lower than normal on most measures of verbal working
memory. Another study examined patients with tumors in the
frontal or temporal lobe and found that more than 90% of their
sample displayed impairment in at least one area of cognition.11
These studies examined the impact of malignant brain tumors
preoperatively and their effect on neuropsychological functioning,
yet altered neuropsychological functioning and its effect on occu-
pational functioning is not reported; thus, the tumor’s impact on
productivity and quality of life is less well known. Alterations in
neuropsychological functioning in patients with skull base brain
tumors could affect their job performance and employment sta-
tus. The purpose of this analysis was to determine neuropsycho-
logical functioning of patients with skull base tumors and
examine its relation to patients’ perceptions of work limitations
and their ability to fulfill occupational demands.
Materials and Methods
Data for this interim analysis were obtained from a large prospec-
tive longitudinal study examining outcomes of patients sched-
uled to undergo endoscopic assisted microneurosurgery or the
use of the expanded endonasal approach for brain tumor resec-
tion. Inclusion criteria were recent diagnosis (within 1 month)
with a midline brain tumor as determined by MRI, aged 18
years or older, and ability to read and speak English. Patients
with a previous history of surgery for brain tumor removal and/
or who had a tumor located in the region of the foramen mag-
numwere excluded from the larger parent study. For this analysis,
data were gathered from participants diagnosed via surgical pa-
thology with any benign skull base lesion, including pituitary ad-
enomas, meningiomas, and Rathke cleft cysts.
Following Institutional Review Board approval, participants
were recruited through the neurosurgery clinic at a Level 1 trau-
ma center, which serves as a major referral source for western
Pennsylvania, northern West Virginia, and eastern Ohio. Eligible
participants were identified by clinic staff, and permission was ob-
tained by the staff for research personnel to approach the partic-
ipant. A member of the research team completed a screening
enrollment form, explained the study, and obtained written con-
sent. Data were collected via in-person assessments 1–2 days
prior to surgical intervention.
Measures
Depressive Symptoms
Study participants completed the Center for Epidemiological
Studies - Depression (CESD)-10,20 a widely used, validated, and
reliable instrument, especially for studies focusing on depressive
symptoms in nonpsychiatric populations. Total CES-D-10 scores
range from 0–30, with higher scores indicating higher levels of
depressive symptoms.
Profile of Mood States-Short Form (POMS-SF)
The Tension/Anxiety subscale of the POMS-SF21 was administered
to assess anxiety. The internal consistency rating for the POMS-SF
is 0.76–0.95. The correlation between the subscales and the total
score in POMS and POMS-SF was calculated as 0.84. The short-
ened anxiety subscale of the POMS-SF scores range from 0–20,
with higher scores indicating higher levels of anxiety.
Work Functioning
The purpose of the analysis was not to discern the impact of neu-
ropsychological function on return to work but rather to evaluate
person’s limitations in performing specific tasks within a job. Neu-
ropsychological dysfunction is often a “hidden” limitation, one
that may not be readily apparent. However, the ability to perform
tasks on the job is heavily dependent upon neuropsychological
function, and thus work limitations are a more sensitive indicator
of an employee’s ability to be productive. Participants completed
the Work Limitations Questionnaire (WLQ),22 a 25-item self-
report measure of work functioning. The WLQ has shown reliabil-
ity and validity for use among several different job and chronic
health condition groups. Reliability of the WLQ subscales is
good, with Cronbach alphas ranging from 0.88 to 0.9. The validity
of the WLQ is well established in the literature and ranges from
0.53 to 0.83. The WLQ questionnaire yields 4 subscale scores
and a total score. Each WLQ subscale score reflects the percent-
age of time in the past 2 weeks that the respondent was limited in
performing a specific dimension of his or her job (Time, Physical,
Mental/ Interpersonal, and Output). The Time Management sub-
scale addresses difficulty meeting a job’s time and scheduling de-
mands. The Physical Demands subscale refers to an individual’s
ability to perform job tasks that involve bodily strength,
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movement, endurance, coordination, and flexibility. The Mental/
Interpersonal domain of theWLQ assesses both the difficulty per-
forming cognitive job tasks or tasks involving the processing of
sensory information as well as the problems a person encounters
while interacting with people on the job. The Output subscale re-
fers to difficulty meeting demands for quantity, quality, and time-
liness of completed work. The WLQ Productivity Loss Score is
based on a weighted sum of the 4 subscale scores and indicates
the percentage decrement in work output due to health prob-
lems. The WLQ Productivity Loss Score expresses the estimated
percent differences in output compared with employees who do
not have health-related work limitations.
Neuropsychological Assessment
The reliability and validity of each of the neuropsychological tests
administered have been well established in the literature. Several
domains of neuropsychological function were assessed: learning
and memory, attention and mental flexibility, executive function,
psychomotor/speed, and language.
Learning and Memory
Auditory Verbal Learning Test
Administration of the Auditory Verbal Learning Test (AVLT)23 in-
cludes 5 successive presentations of a list of 15 common words
followed by free recall on each trial, an interference trial (presen-
tation and recall of a list of 15 different words), postinterference
recall of the words from the original list, and a delayed (30 min)
recall. The AVLT test is used to assess immediate and delayed ver-
bal learning and memory, memory acquisition, and retention.
Rey-Osterrieth Figure Test
The Rey-Osterrieth Figure Test (ROCF)24 assesses visual perceptu-
al, skills, spatial organization, constructional ability, and visual
memory (immediate and delayed recall). Participants are in-
structed to carefully copy a figure and then to redraw the
figure immediately after the figure is removed and again in
30 minutes (delayed recall).
Wechsler Memory Scale III, Logical Memory Subtest
With the Wechsler Memory Scale III (WMS-III), Logical Memory
Subtest (LM I-II),25 participants are read 2 short stories out
loud and asked to retell the stories from memory immediately
and after a 30 minute delay. Story A is read only once, whereas
Story B is read twice. Participants are credited for each correctly
recalled detail (maximum of 25) and for general themes (maxi-
mum Story A¼ 7, Story B¼ 8). The WMS-III assesses verbal
learning and memory (short- and long-term), logical memory,
and retention.
Attention and Mental Flexibility
Wechsler Adult Intelligence Scale III, Digit Symbol
Coding Subtest
In the Digit Symbol Coding Subtest,26 participants are presented
with a key of symbols paired with numbers under which is a series
of rows with randomly ordered numbers. Using the key, partici-
pants are instructed to draw the corresponding symbol under
each number as fast as they can. The score is determined by
the number of symbols correctly drawn within the 120 second
time limit. This test assesses psychomotor response speed, visuo-
motor coordination, and attention.
Trail Making Test
Both Trail Making Tests (TMTA and B)27 consist of 25 circles distrib-
uted across a sheet of paper. In Test A, circles are numbered from
1 to 25, and the participant is asked to draw lines connecting the
numbers in ascending order. In Test B, the circles include both
numbers (1–13) and letters (A-L). Similar to Test A, the partici-
pant is asked to connect the circles in ascending order, but with
the additional task of alternating between letters and numbers
(ie, 1-A-2-B-3-C, etc.). Participants are instructed to draw lines
connecting the circles in order as quickly as possible for each
test without lifting the pencil from the paper. The TMT scores re-
flect the total number of seconds it took to complete each trial.
The TMT tests assess executive function, mental flexibility, and
attention.
Executive Function
Stroop Color Word Test
With the Stroop Color Word Test,28 participants are given a book-
let with the colors blue, red, or green listed in random order in 5
columns of 20 colors. They are asked to read the colors out loud,
going down each column as fast as they can. The test consists of
3 trials measuring the relative speed of a person’s ability to read
the names of colors (W), naming colors (C), and naming colors
from words of colors printed with an incongruently colored ink.
The Stroop Color Word Test is scored by reporting the number of
colors read in 45 seconds for each trial and assesses executive
functioning through inhibition and cognitive flexibility through
interference.
Psychomotor/Speed
Grooved Peg Board Test
The Grooved Peg Board Test (GPT)29 uses a metal board with rows
of slotted holes angled in different directions. The task is to insert
25 metal pegs with ridges on the sides into each hole in seq-
uential order. Participants are asked to do the first trial with
their dominant hand, and then repeat the task with their non-
dominant hand. The score is based on the time it takes to fill in
all the holes and the number of pegs dropped for each trial; higher
scores indicate poorer function. The Grooved Peg Board Test eval-
uates psychomotor speed, fine motor control, and visual-motor
coordination.
Language
Controlled Oral Word Association Test F, A, S and
Animal Naming
In the Controlled Oral Word Association Test (COWAT) F, A, S, and
Animal Naming30 test of verbal fluency, participants are
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instructed to orally generate as many words as they can, begin-
ning with the letters F, A, and S, as well as name as many animals
as they can in 60 seconds for each trial. The COWAT assesses ex-
ecutive function, auditory attention, short-term memory, cogni-
tive flexibility, and vocabulary. The score is generated based on
the total number of words produced in each trial.
Estimated General Intelligence
North American Adult Reading Test
The North American Adult Reading Test (NAART-R)31 requires par-
ticipants to read and pronounce a list of 61 irregularly spelled
words (eg, debt, gauge, leviathan). It provides an excellent esti-
mate of premorbid verbal intelligence, which has been shown
to be resistant to the effects of acquired brain damage.
Analysis
There was a sample size calculation performed for the larger par-
ent study; however, this pilot analysis used a subset of the larger
study. Descriptive analyses were conducted to explore the fre-
quency and distribution of the independent and dependent vari-
ables. To examine relationships between sociodemographic
characteristics, estimated general intelligence, mood, neuropsy-
chological domains, and work limitations in each WLQ subscale
and total sum score, 2-tail t tests and Pearson correlations
were conducted. Variables that reached statistical significance
of P, .10 were included as potential predictor variables in the
multiple linear regression model. Separate backward multiple lin-
ear regression analyses were conducted for each WLQ subscale
and total sum score to model the impact of neuropsychological
function on work productivity, controlling for general intelligence,
depression, and anxiety scores. All analyses were performed
using SPSS version 19.
Results
Approximately 75% of the patients approached agreed to partic-
ipate in this study. A total of 45 participants were included in this
analysis (see Table 1). Almost all participants had more than one
symptom complaint prior to resection. More than 60% of partic-
ipants reported headaches (n¼ 27), andmore than 30% reported
visual disturbances (n¼ 14). Other reported symptoms included
endocrinopathies (acromegaly, Cushing’s syndrome, and dysme-
norrhea), sexual dysfunction (decreased libido, erectile dysfunc-
tion, and infertility), and mood disturbances (anxiety and
depression). The majority of participants were white females
with an average age of 43.1 years (SD¼ 13.17). The average
number of years of formal education was 15.05, equivalent to
some college education. Seventy-one percent of all participants’
tumors were classified as adenomas with an average tumor vol-
ume of 4.27 cc. Categorizing participants’ jobs according to the
International Standard Classification of Occupations revealed
that participants were most likely to be professionals or clerical
support workers (40%, n¼ 18).26
Descriptive statistics for participants’ performance on preoper-
ative neuropsychological tests are reported in Table 2 as com-
pared with mean and standard deviations found in population
normative data.25,32 Sample mean scores on neuropsychological
tests were within one standard deviation of population normative
values; thus, it was assumed that the sample’s overall neuropsy-
chological status did not significantly differ from that of the gene-
ral population.
Descriptive statistics for participants’ perception of work limi-
tations (as measured by the WLQ questionnaire) can be found
in Table 3. Overall, participants with skull base tumors reported
the highest dysfunction in the time management subscale. The
percentage of time in the past 2 weeks that participants were lim-
ited in performing timemanagement skills was 27.09%. Difficulty
meeting mental/interpersonal demands presented the second
highest level of dysfunction in work functioning for participants,
followed by difficulty meeting physical demands, and finally, dif-
ficulty meeting output demands. Calculations of total percent
health-related work productivity loss yielded a mean productivity
loss of 6.15% in participants with a skull base tumor.
Table 4 contains the results of the multiple linear regression
analyses examining the relationship between domains of neuro-
psychological function and work limitations. The first subscale of
the WLQ was time management. Greater difficulties with time
management were predicted by poorer mental attention and
flexibility (b¼20.59, P¼ .01) as measured by the Digit Symbol
Coding task and higher depressive symptoms (b¼ 3.42, P, .01)
as measured by the CES-D (total model R2¼ 0.55, P, .01).
Table 1. Sociodemographic characteristics of sample (n¼ 45)
Characteristic Mean (SD) or n (%)
Years of education 15.05 (2.75)
Age (years) 43.4 (13.17)
Tumor volume(cc)* 4.27 (7.16)
Sex
Male 17 (37.8%)
Female 28 (62.2%)
Race
White 36 (87.8%)
Black 4 (9.8%)
Hispanic 1 (2.4%)
Tumor type
Adenoma 32 (71.1%)
Meningioma 7 (15.6%)
Rathke’s cleft cyst 6 (13.3%)
Job classification
Managers 5 (11.1%)
Professionals 9 (20.0%)
Technicians and associate professionals 5 (11.1%)
Clerical support workers 9 (20.0%)
Service and sales workers 7 (15.6%)
Skilled agricultural, forestry, and fishery workers 1 (2.2%)
Craft and related-trades workers 4 (8.9%)
Plant and machine operators 2 (4.4%)
Elementary occupations 1 (2.2%)
Unemployed** 2 (4.4%)
*Resultafter removing one outlier.
**The participantquit work immediately before an expanded endonasal
approach procedure.
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Difficultymeeting the physical demands of work was predicted
by poorer visuospatial ability (b¼23.30 P¼ .05) as measured by
the Rey Figure Copy task and higher depressive symptoms (b¼
2.29, P, .01) (total model R2¼ 0.29, P, .01). Problems meeting
the mental/interpersonal demands of work were associated with
poorer verbal learning and memory (b¼23.394, P¼ .04) as
measured the AVLT delay and higher depressive symptoms (b¼
3.246, P, .01) (total model R2¼ 0.47, P, .01).
There were no significant associations between difficulty
meeting output demands and performance on any neuropsycho-
logical measures that were administered.
The total percent of health-related loss of work productivity
was calculated by a weighted summing of the 4 subscales of
the WLQ (Time, Physical, Mental/Interpersonal, and Output).
Lower learning and memory scores, specifically lower scores on
AVLT learning delay test, significantly predicted total work produc-
tivity loss (b¼20.72, P¼ .05). Higher reports of depressive symp-
toms were also associated with greater loss of work productivity
(b¼ .66, P, .01) (total model R2¼ 0.43, P, .01).
Discussion
Findings from this study revealed that certain neuropsychological
tests may predict work limitations in patients with skull base tu-
mors. It is worth noting that, although the sample mean was
similar to that of the general population, slight individual differ-
ences could not be detected given the small sample size. A mul-
tivariate regression analysis revealed that neuropsychological
tests were found to predict occupational functioning despite
the overwhelming majority of persons included in this study
who scored within published population normative values. Diffi-
culties with tasks of mental attention and flexibility and learning
and memory, as well as visuospatial dysfunction and higher de-
pressive symptoms, were significantly associated with difficulty in
one or more subscales of work life.
Subscales of work life represent various aspects of work pro-
ductivity. Time management indicates the ability to handle
scheduling, organizing, and prioritizing tasks to accomplish a
goal. Measuring physical demands provides insight into whether
a person is able to coordinate movement and has the strength
and endurance to accomplish a task. Lower scores on the men-
tal/interpersonal demands subscale indicate that a person has
deficits in cognitively processing information and working with
others in the occupational setting to accomplish a task. Finally,
limitations in the output demands subscale indicate that a per-
son’s productivity is at risk, either from decreased quantity and/
or quality of work. Neuropsychological functions that affect
these areas of occupational productivity are described in the fol-
lowing sections.
Specifically, the Digit Symbol Coding Test (a measure of atten-
tion andmental flexibility) was useful for predicting difficulty with
time management at work. Poorer performance on the Rey
Table 3. Percent decrement in work functioning
Work domain n Mean (SD)
Time 45 27.09 (25.84)
Physical 42 25.07 (24.89)
Mental/Interpersonal 45 26.02 (27.54)
Output 44 19.79 (25.18)
Total 41 6.15 (5.89)
Table 2. Comparison of sample neuropsychological test scores to normative data
Cognitive Domain Neuropsychological Test Expected Score (SD)* Sample Mean (SD)
Verbal learning AVLT learning slope (V-I) 5.8 (1.7) 5.6 (1.5)
Logical Memory learning slope (WMS-III) 5.0 (3.0) 5.2 (2.7)
Verbal memory AVLT delayed recall 10.2 (2.8) 8.3 (2.6)
Logical Memory total unit delayed recall
(WMS-III)
24.0 (11.0) 26.4 (7.1)
Logical memory Logical Memory total theme delayed recall
(WMS-III)
11.0 (3.0) 12.1 (2.5)
Spatial organization ROCF copy 34.4 (2.3) 34.0 (2.2)
Constructional ability ROCF recall 23.6 (6.9) 20.0 (5.6)
Visual memory ROCF delayed recall 23.1 (6.7) 19.6 (4.9)
Executive function TMT B time 64.6 (22.3) 59.9 (17.7)
Stroop color/word T-score 50 (10) 47.0 (8.8)
Verbal fluency COWAT total FAS 45.1 (11.2) 39.0 (11.0)
COWAT animal naming 23.0 (4.7) 19.0 (5.7)
Psychomotor processing speed and visual-motor
coordination
Digit Symbol Coding 75.0 (3.0) 74.5 (16.6)
GPT nondominant hand 72.9 (15.3) 84.3 (23.6)
Abbreviations: AVLT, Auditory Verbal Learning Test; COWAT, Controlled Oral Word Association Test; GPT, Grooved Peg Test; ROCF, Rey-Osterrieth
Figure Test; TMT, Trail Making Tests; WMS, Wechsler Memory Scale.
*Expected scores were obtained from the Wechsler Memory Scale: Third Edition Manual25and the Handbook of normative data for neuropsychological
assessment.32
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Figure Copy task, a measure of visuospatial ability, was a predictor
for difficulties managing the physical demands associated with
work. Poorer performance on the AVLT learning delay test predict-
ed difficulty meeting the mental and interpersonal demands of
work. As other studies have shown,33,34 reports of greater number
of depressive symptoms were highly correlated with difficulties
meeting the time management, physical, and mental/interper-
sonal demands of work as well as the overall percent of health-
related work productivity loss.
The Digit Symbol Coding test was developed to assess atten-
tion andmental flexibility under time pressure. The timemanage-
ment subscale of occupational functioning includes the ability to
meet demands for quantity, quality, and timeliness of work com-
pleted; thus, it is not surprising that the results of this study found
the Digit Symbol Coding test to be a predictor of time manage-
ment in an occupational setting. The Rey Figure Copy Task is a
test used to assess visuospatial ability and motor functioning.
In this study, the Rey Figure Copy Task was found to be a predictor
of difficulties meeting the physical demands of a person’s occu-
pation. The results of this study, which found that the AVLT pre-
dicted ability to meet mental/interpersonal demands, have
been shown in other studies,33,34 although in different popula-
tions such as patients who had experienced a traumatic brain in-
jury and patients with primary brain tumors. In relation to
interpersonal demands, a study of patients with traumatic brain
injury reported that the AVLT predicted difficulty with social adap-
tation.33 The association between AVLT and mental, or cognitive,
impairment was also found in a study examining patients with
primary brain tumors prior to intervention.34 Consistent with find-
ings from other studies, neuropsychological tests that assess vi-
suospatial ability and psychomotor skills may be useful for
predicting work dysfunction.
Previous studies have been conducted examining the influ-
ence of depression on work productivity. These studies, however,
relied on the classification of patients as “depressed” or “nonde-
pressed.” The current study correlated their measure of self-
reported depressive symptoms on the CES-D, although
interestingly, very few of these patients actually met the criteria
for being at risk for clinical depression. Past research in patients
with pituitary adenomas has shown that these individuals have
a higher incidence of mood disorders, including depression,
than the general population.35–37 Examining the scatter plot of
CES-D scores, as it correlates with occupational difficulty (Fig. 1),
revealed that many of the participants with skull base tumors
showed decrements in neuropsychological functioning and diffi-
culty completing occupational tasks beginning with a CES-D score
of 10.
The clinical implications of this study include recognizing that
patients with skull base tumors have the potential to experience
altered neuropsychological function that may limit their ability to
meet the demands of their occupation in one or more areas of
work life. It is worth noting that 95% of participants remained
employed (n¼ 34) and that 5% (n¼ 2) quit work immediately
prior to surgery. Thus, although individuals may remain em-
ployed, assessment of individuals may be important to detect un-
derperformance in particular areas of work functioning.
The potential for work limitations may be predictable using the
individual’s performance on specific neuropsychological tests.
Specifically, difficulty on tests of attention and mental flexibility,
learning and memory, visuospatial ability, and scoring higher
than a 10 on the CES-D may indicate that the individual is more
likely to experience work limitations. Careful screening of patients
with skull base tumors may be able to help better identify those
patients who are at particular risk for work limitations in order
to intervene and ameliorate the distress or limitations they
experience.
This study has shown that higher levels of depressive symp-
toms are consistently correlated with a decline in the ability to
meet occupational demands. Brief screening tools for depressive
symptoms are already implemented in many physician practices.
Clinicians should recognize that the presence of depressive symp-
toms may predict occupational difficulties and should be prepared
to discuss this with patients. Patients who undergo neuropsycho-
logical testing and exhibit difficulty in the visuospatial, attention
Table 4. Neuropsychological predictors of work limitations
Domain Test b SE P
Time R2¼ 0.55; Model P, .01
Digit Symbol Coding 20.59 0.22 .01
Depression (CES-D) 3.42 0.63 ,.01
Physical R2¼ 0.29; Model P, .01
Rey Figure Copy 23.30 1.63 .05
Depression (CES-D) 2.29 0.65 ,.01
Mental/ Interpersonal R2¼ 0.47; Model P, .01
AVLT learning delay 23.39 1.56 .04
Depression (CES-D) 3.25 0.68 ,.01
Output* R2¼ 0.07; Model P¼ .10
– – – –
Total Work Loss R2¼ 0.43; model P, .01
AVLT learning delay 20.72 0.35 .05
Depression (CES-D) 0.66 0.16 ,.01
Abbreviations: AVLT, Auditory Verbal Learning Test; CES-D, Center for Epidemiological Studies – Depression.
*No neuropsychological tests were found to significantly predict difficulty in the Output domain of work functioning.
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and mental flexibility, or learning and memory domains should
also be screened for difficulty meeting occupational demands.
Any patients experiencing occupational dysfunction should then
be referred for supportive or rehabilitative services in order tomain-
tain the highest level of functioning possible.
The research implications of this study include recognizing that
even mild reporting of depressive symptoms on the CES-D may
help to identify patients at risk for difficulty meeting occupational
demands. Findings from this study also raise questions as to
whether or not patients with benign skull base tumors are able
to maintain optimal occupational functioning. Further research
should follow these patients longitudinally to assess the relation-
ships between changes in neuropsychological and occupational
functioning over time.
Limitations
The sample size was relatively small and largely homogenous in
terms of race. A more diverse population may help verify whether
these findings hold true for racially diverse groups and for all ages.
This study also lacked a control group, so it is unclear how individ-
uals with skull base tumors might differ in comparison with a
group of healthy controls without a symptomatic skull base
tumor. Patients’ work status is self-reported, as is their function-
ing at work. Thus, patients’ perceptions of their occupational
functioning may differ significantly from their employers’ percep-
tions or from objective measures of occupational functioning. Fi-
nally, a larger sample may help to detect any differences in
occupational or neuropsychological dysfunction related to
tumor type.
Funding
National Institute of Health, National Institute of Nursing Research, Pa-
tient and Health Care System Outcomes Following EEA (1 R01
NR011044-01), Bethany D. Nugent, Jason Weimer, Chienwen J. Choi,
Paula R. Sherwood.
National Institute of Health, National Institute of Nursing Research,
Predoctoral Fellowship in Interdisciplinary Training of Nursing Scientists in
Cancer Survivorship Research (T32 NR011972), Bethany D. Nugent.
Acknowledgments
Portions of this work were presented in a podium presentation at the
Oncology Nursing Society (ONS) Connections Conference, Phoenix,
Arizona, November 9, 2012.
Conflict of interest statement: None declared.
References
1. (CBTRUS) CBTR of the US. CBTRUS incidence rates adjusted using the
Year 2000 United States standard population. 2000. Available at:
www.cbtrus.org. Accessed March 12, 2013.
2. Radhakrishnan K, Mokri B, Parisi JE, O’Fallon WM, Sunku J, Kurland LT.
The trends in incidence of primary brain tumors in the population of
Rochester, Minnesota. Ann Neurol. 1995;37(1):67–73.
3. Claus EB, Bondy ML, Schildkraut JM, Wiemels JL, Wrensch M, Black
PM. Epidemiology of Intracranial Meningioma. Neurosurgery. 2005;
57(6):1088–1095.
4. Ezzat S, Asa SL, Couldwell WT, et al. The prevalence of pituitary
adenomas: a systematic review. Cancer. 2004;101(3):613–9.
5. Surawicz TS, McCarthy BJ, Kupelian V, Jukich PJ, Bruner JM, Davis FG.
Descriptive epidemiology of primary brain and CNS tumors: results
from the Central Brain Tumor Registry of the United States, 1990–
1994. Neuro Oncol. 1999;1(1):14–25.
6. Vernooij MW, Ikram MA, Tanghe HL, et al. Incidental findings on
brain MRI in the general population. N Engl J Med. 2007;357(18):
1821–8.
7. Voelker JL, Campbell RL, Muller J. Clinical, radiographic, and pathological
features of symptomatic Rathke’s cleft cysts. J Neurosurg. 1991;74:
535–544.
8. Social Security Administration. Disability Evaluation Under
Social Security. 2014. Available at: http://www.ssa.gov/disability/
professionals/bluebook/11.00-Neurological-Adult.htm. Accessed
March 6, 2013.
9. Kangas M, Tate RL, Williams JR, Smee RI. The effects of radiotherapy
on psychosocial and cognitive functioning in adults with a primary
brain tumor: a prospective evaluation. Neuro Oncol. 2012;14(12):
1485–502.
10. Costello AB, Osborne JW. Best practices in exploratory factor
analysis: Four recommendations for getting the most from your
analysis. Pract Assessment, Res Eval. 2005;10(7):1–9.
11. Tucha O, Smely C, Preier M, Lange KW. Cognitive deficits before
treatment. Neurosurgery. 2000;47(2):324–334.
12. Van Nieuwenhuizen D, Ambachtsheer N, Heimans JJ, Reijneveld JC,
Peerdeman SM, Klein M. Neurocognitive functioning and
health-related quality of life in patients with radiologically
suspected meningiomas. J Neurooncol. 2013;113(3):433–40.
Fig. 1. Percent of health-related work productivity loss as a function of
CES-D score. A scatterplot was generated to visualize each participant’s
percent of health-related work productivity loss as measured on the
WLQ (X-axis) as a function of individual CES-D scores, which are a
measure of depressive symptomatology (Y-axis). There appears to be a
trend towards increased percent of work-productivity loss with higher
levels of depressive symptoms.
Nugent et al.: Work productivity and skull base tumors
112 Neuro-Oncology Practice
13. Acoustic Neuroma Association. Treatment Options. 2014. Available
at: http://anausa.org. Accessed February 20, 2014.
14. White ML, Doherty GM. Multiple endocrine neoplasia. Surg Oncol Clin
N Am. 2008;17:439–459.
15. Heaton RK, Chelune GJ, Lehman RA. Using neuropsychological and
personality tests to assess the likelihood of patient employment. J
Nerv Ment Dis. 1978;166(6):408–416.
16. Kibby MY, Schmitter-Edgecombe M, Long CJ. Ecological validity of
neuropsychological tests: Focus on the California Verbal Learning
Test and Wisconsin Card Sorting Test. Arch Clin Neuropsychol. 1998;
13(6):523–534.
17. McGurk SR, Meltzer HY. The role of cognition in vocational functioning
in schizophrenia. Schizophr Res. 2000;45(3):175–84.
18. Rabkin JG McElhiney M, Ferrando SJ, Van GorpW, Lin SH. Predictors of
employment of men with HIV/AIDS: a longitudinal study. Psychosom
Med. 2004;66(1):72–78.
19. Teixidor P, Gatignol P, Leroy M, Masuet-Aumatell C, Capelle L, Duffau
H. Assessment of verbal working memory before and after surgery
for low-grade glioma. J Neurooncol. 2007;81(3):305–13.
20. Radloff L. The CES-D Scale: A self-report depression scale for research
in the general population. Appl Psychol Meas. 1977;1(3):385–401.
21. Shacham S. A shortened version of the Profile of Mood States. J Pers
Assess. 1983;47(3):305–306.
22. Lerner D, Amick BC, Rogers WH, Malspeis S, Bungay K, Cynn D. The
Work Limitations Questionnaire. Med Care. 2001;39(1):72–85.
23. Rey A. L’examen clinique en psychologie. Paris: Presses Universitaires
de France; 1964.
24. Rey A, Osterrieth P. Translations of excerpts from Andre Rey’s
psychological examination of traumatic encephalopathy and
P. A. Osterrieth’s The Complex Figure Copy Test. Clin Neuropsychol.
1993;7(1):4–21.
25. Wechsler D. Wechsler Memory Scale: Third Edition Manual. San
Antonio: The Psychological Corporation; 1997.
26. Wechsler D. Wechsler Adult Intelligence Scale-III. San Antonio: The
Psychological Corporation; 1997.
27. Reitan RM. The relation of the trail making test to organic brain
damage. J Consult Psychol. 1955;19(5):393–4.
28. Golden CJ. Stroop Color and Word Test. Lutz: PAR/Psychological
Assessment Resources; 2002.
29. Trites R. Instruction Manual for the Grooved Peg Board Test. Lafayette:
Lafayette Instrument Company, Inc.; 1989.
30. Benton AL, Hamsher KD. Controlled Oral Word Association
Test, multilingual aphasia examination. Iowa City: AJA Associates;
1989.
31. Blair JR, Spreen O. Predicting premorbid IQ: A revision of the National
Adult Reading Test. Clin Neuropsychol. 1989;3:129–136.
32. Mitrushina M. Handbook of Normative Data for Neuropsychological
Assessment. 2nd ed. New York: Oxford University Press; 2005.
33. Ross SR, Millis SR, Rosenthal M. Neuropsychological prediction of
psychosocial outcome after traumatic brain injury. Appl
Neuropsychol. 1997;4(3):165–170.
34. Scotland JL, Whittle IR, Deary IJ. Cognitive functioning in newly
presenting patients with supratentorial intracranial tumors: is
there a role for inspection time?. Neuro Oncol. 2012;14(3):360–7.
35. Weitzner M. Apathy and pituitary disease: it has nothing to do with
depression. J Neuropsychiatry Clin Neurosci. 2005;17(2):159–66.
36. Korali Z, Wittchen HU, Pfister H, Ho¨fler M, Oefelein W, Stalla GK. Are
patients with pituitary adenomas at an increased risk of mental
disorders?. Acta Psychiatr Scand. 2003;107(1):60–8.
37. Johnson MD, Woodburn CJ, Vance ML. Quality of life in patients with
a pituitary adenoma. Pituitary. 2003;6(2):81–7.
Nugent et al.: Work productivity and skull base tumors
Neuro-Oncology Practice 113
APPENDIX B
LICENSE AGREEMENT FOR PRELIMINARY WORK MANUSCRIPT #1
59
&ƌŽŵ͗:KhZE>^WZD/^^/KE^^ĞŶƚ͗DŽŶĚĂǇ͕DĂǇϭϲ͕ϮϬϭϲϭϬ͗ϯϰDdŽ͗EƵŐĞŶƚ͕ĞƚŚĂŶǇŝĂŶĞ^ƵďũĞĐƚ͗Z͗tŽƵůĚůŝŬĞƚŽŝŶĐůƵĚĞƉĂƉĞƌŝŶĚŝƐƐĞƌƚĂƚŝŽŶĚŽĐƵŵĞŶƚ
ĞĂƌĞƚŚĂŶǇ͕
Z͘ĞƚŚĂŶǇ͘EƵŐĞŶƚĞƚĂů͘tŽƌŬWƌŽĚƵĐƚŝǀŝƚǇĂŶĚEĞƵƌŽƉƐǇĐŚŽůŽŐŝĐĂů&ƵŶĐƚŝŽŶŝŶWĞƌƐŽŶƐǁŝƚŚ^ŬƵůůĂƐĞdƵŵŽƌƐ͘EĞƵƌŽͲKŶĐŽůŽŐǇWƌĂĐƚŝĐĞ;ϮϬϭϰͿϭ;ϯͿ͗ϭϬϲͲϭϭϯ
DǇĂƉŽůŽŐŝĞƐĨŽƌƚŚĞĚĞůĂǇĂŶĚƚŚĂŶŬǇŽƵĨŽƌǇŽƵƌƌĞĐĞŶƚĞŵĂŝůƌĞƋƵĞƐƚŝŶŐƉĞƌŵŝƐƐŝŽŶƚŽƌĞƵƐĞĂůůŽƌƉĂƌƚŽĨǇŽƵƌĂƌƚŝĐůĞŝŶĂƚŚĞƐŝƐ͘
ƐƉĂƌƚŽĨǇŽƵƌĐŽƉǇƌŝŐŚƚĂŐƌĞĞŵĞŶƚǁŝƚŚKǆĨŽƌĚhŶŝǀĞƌƐŝƚǇWƌĞƐƐǇŽƵŚĂǀĞƌĞƚĂŝŶĞĚƚŚĞƌŝŐŚƚ͕ĂĨƚĞƌƉƵďůŝĐĂƚŝŽŶ͕ƚŽƵƐĞĂůůŽƌƉĂƌƚŽĨƚŚĞĂƌƚŝĐůĞĂŶĚĂďƐƚƌĂĐƚ͕ŝŶƚŚĞƉƌĞƉĂƌĂƚŝŽŶŽĨĚĞƌŝǀĂƚŝǀĞǁŽƌŬƐ͕ĞǆƚĞŶƐŝŽŶŽĨƚŚĞĂƌƚŝĐůĞŝŶƚŽĂďŽŽŬůĞŶŐƚŚǁŽƌŬ͕ŝŶĂƚŚĞƐŝƐͬĚŝƐƐĞƌƚĂƚŝŽŶ͕ŽƌŝŶĂŶŽƚŚĞƌǁŽƌŬƐĐŽůůĞĐƚŝŽŶ͕ƉƌŽǀŝĚĞĚƚŚĂƚĂĨƵůůĂĐŬŶŽǁůĞĚŐĞŵĞŶƚŝƐŵĂĚĞƚŽƚŚĞŽƌŝŐŝŶĂůƉƵďůŝĐĂƚŝŽŶŝŶƚŚĞũŽƵƌŶĂů͘ƐĂƌĞƐƵůƚ͕ǇŽƵƐŚŽƵůĚŶŽƚƌĞƋƵŝƌĞĚŝƌĞĐƚƉĞƌŵŝƐƐŝŽŶĨƌŽŵKǆĨŽƌĚhŶŝǀĞƌƐŝƚǇWƌĞƐƐƚŽƌĞƵƐĞǇŽƵĂƌƚŝĐůĞ͘
,ŽǁĞǀĞƌ͕ŝŶůŝŶĞǁŝƚŚƚŚĞũŽƵƌŶĂůƐĞůĨͲĂƌĐŚŝǀŝŶŐƉŽůŝĐǇ͕ǇŽƵŵĂǇŽŶůǇŝŶĐůƵĚĞǇŽƵƌĂĐĐĞƉƚĞĚŵĂŶƵƐĐƌŝƉƚW& ŝŶǇŽƵƌƚŚĞƐŝƐ͕ĂŶĚƉƵďůŝĐĂǀĂŝůĂďŝůŝƚǇŵƵƐƚďĞĚĞůĂǇĞĚƵŶƚŝůϭϮŵŽŶƚŚƐ ĂĨƚĞƌĨŝƌƐƚŽŶůŝŶĞƉƵďůŝĐĂƚŝŽŶŝŶƚŚĞũŽƵƌŶĂů͘zŽƵƐŚŽƵůĚŝŶĐůƵĚĞƚŚĞĨŽůůŽǁŝŶŐĂĐŬŶŽǁůĞĚŐŵĞŶƚĂƐǁĞůůĂƐĂůŝŶŬƚŽƚŚĞǀĞƌƐŝŽŶŽĨƌĞĐŽƌĚ͘WůĞĂƐĞŶŽƚĞŝŶĐůƵƐŝŽŶƵŶĚĞƌĂƌĞĂƚŝǀĞŽŵŵŽŶƐůŝĐĞŶƐĞŽƌĂŶǇŽƚŚĞƌŽƉĞŶͲĂĐĐĞƐƐůŝĐĞŶƐĞĂůůŽǁŝŶŐŽŶǁĂƌĚƌĞƵƐĞŝƐƉƌŽŚŝďŝƚĞĚ͘
dŚŝƐŝƐĂƉƌĞͲĐŽƉǇĞĚŝƚĞĚ͕ĂƵƚŚŽƌͲƉƌŽĚƵĐĞĚW&ŽĨĂŶĂƌƚŝĐůĞĂĐĐĞƉƚĞĚĨŽƌƉƵďůŝĐĂƚŝŽŶŝŶ΀ŝŶƐĞƌƚũŽƵƌŶĂůƚŝƚůĞ΁ĨŽůůŽǁŝŶŐƉĞĞƌƌĞǀŝĞǁ͘dŚĞǀĞƌƐŝŽŶŽĨƌĞĐŽƌĚ΀ŝŶƐĞƌƚĐŽŵƉůĞƚĞĐŝƚĂƚŝŽŶŝŶĨŽƌŵĂƚŝŽŶŚĞƌĞ΁ŝƐĂǀĂŝůĂďůĞŽŶůŝŶĞĂƚ͗΀ŝŶƐĞƌƚhZ>ƚŚĂƚƚŚĞĂƵƚŚŽƌǁŝůůƌĞĐĞŝǀĞƵƉŽŶƉƵďůŝĐĂƚŝŽŶŚĞƌĞ΁͘
&ŽƌĨƵůůĚĞƚĂŝůƐŽĨŽƵƌƉƵďůŝĐĂƚŝŽŶĂŶĚƌŝŐŚƚƐƉŽůŝĐǇƉůĞĂƐĞƐĞĞƚŚĞĂƚƚĂĐŚĞĚůŝŶŬƚŽŽƵƌǁĞďƐŝƚĞ͗ŚƚƚƉ͗ͬͬǁǁǁ͘ŽǆĨŽƌĚũŽƵƌŶĂůƐ͘ŽƌŐͬĞŶͬĂĐĐĞƐƐͲƉƵƌĐŚĂƐĞͬƌŝŐŚƚƐͲĂŶĚͲƉĞƌŵŝƐƐŝŽŶƐͬƐĞůĨͲĂƌĐŚŝǀŝŶŐͲƉŽůŝĐǇď͘Śƚŵů
/ĨǇŽƵŚĂǀĞĂŶǇŽƚŚĞƌƋƵĞƌŝĞƐ͕ƉůĞĂƐĞĨĞĞůĨƌĞĞƚŽĐŽŶƚĂĐƚƵƐ͘
<ŝŶĚƌĞŐĂƌĚƐ͕>ŽƵŝƐĞ
DŝƐƐ>ŽƵŝƐĞǇƌĞWĞƌŵŝƐƐŝŽŶƐƐƐŝƐƚĂŶƚͮZŝŐŚƚƐĞƉĂƌƚŵĞŶƚ
ĐĂĚĞŵŝĐĂŶĚ:ŽƵƌŶĂůƐŝǀŝƐŝŽŶƐͮ'ůŽďĂůƵƐŝŶĞƐƐĞǀĞůŽƉŵĞŶƚKǆĨŽƌĚhŶŝǀĞƌƐŝƚǇWƌĞƐƐ'ƌĞĂƚůĂƌĞŶĚŽŶ^ƚƌĞĞƚͮKǆĨŽƌĚͮKyϮϲW
dĞů͗нϰϰ;ϬͿϭϴϲϱϯϱϰϰϱϰͮŵĂŝů͗ůŽƵŝƐĞ͘ĞǇƌĞΛŽƵƉ͘ĐŽŵ
APPENDIX C
PRELIMINARY WORK MANUSCRIPT #2: CANCER AND COGNITIVE
CHANGES THE COMPLEXITY OF THE PROBLEM
61
CANCER AND COGNITIVE
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OBJECTIVES: To describe the factors that influence cognitive function in the
context of cancer and cancer therapy, and to illustrate the complex nature of
the problem.
DATA SOURCES: Peer-reviewed literature.
CONCLUSION: Multiple factors contribute to changes in cognitive function in
this population, including demographic, psychological, and physiological
factors, the disease itself, disease- and treatment-related symptoms, and the
management of those symptoms.
IMPLICATIONS FOR NURSING PRACTICE: Nurses’ recognition of the multiple
factors that may influence cognitive function in patients with cancer should
guide appropriate patient assessment. Appreciation of the complex basis of
the changes in cognitive function in patients with cancer can provide
direction for the appropriate management of the problem.
KEY WORDS: Cognitive function, cancer, cancer therapy, symptoms,
depression
C
OGNITIVE function is a higher order
mental process that involves the
capacity to process information, neces-
sitating integrated action of numerous
areas of the brain.1 Cognitive function encom-
passes multiple domains including attention,
learning and memory, executive function, psycho-
motor efficiency, mental flexibility, visuospatial
ability, and language. These domains are highly
interrelated so that impairment in one domain
can have a deleterious effect on the function of
other cognitive domains. Cognitive function is as-
sessed objectively with batteries of neuropsycho-
logical measures that provide domain-specific
information. Perceived cognitive function also
can be assessed with self-report measures. Demo-
graphic characteristics such as age, gender, and
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years of education, as well as psychological factors
including anxiety and depression, influence cogni-
tive function in adults. In addition, changes in
hormone levels that normally occur over the
course of one’s life, as well as medications taken
to manage other health problems such as hyper-
tension, also may influence cognitive function.2
Abundant evidence exists for changes in cogni-
tive function in patients with cancer.3-7 Most
patients with cancer do not meet criteria for
impairments in cognitive function8; rather, they
experience more subtle deterioration in function
that can impact daily functioning and quality of
life.3 Multiple factors contribute to changes in
cognitive function experienced by patients with
cancer including: demographic, psychological,
and physiological factors, cancer therapy, the
disease itself, disease- and treatment-related symp-
toms, and the management of those symptoms
(Table 1).9 The purpose of this article is to discuss
the factors that influence cognitive function in the
context of cancer and cancer therapy to illustrate
the complex nature of this problem. The physiolog-
ical bases for this problem are described
elsewhere.10
FACTORS INFLUENCING COGNITIVE FUNCTION
Demographic Factors
In general, higher levels of cognitive function are
associated with greater years of education and
higher general intelligence in adults.11 Declines in
cognitive function are associated with advancing
age.11 Differences in cognitive function also may
be based on gender. Gender differences in the level
of functioning of specific domains of cognitive func-
tion include female superiority inverbalfluencyand
articulation, perceptual speed and accuracy, and
fine distal motor movements.11 Male superiority
has been demonstrated in spatial rotation and
manipulation andmathematical reasoning.12 These
differences may be a consequence of the influences
of the prenatal hormonal environment on neuronal
connectivity.13,14 No gender differences exist for
general intelligence.15 Several factors that increase
the risk for deterioration in cognitive function
include advancing age, lower IQ, a history of neuro-
logical or psychiatric illness or developmental disor-
ders, a history of substance abuse, and prior cancer
therapy.16
Psychological Factors
Depression and anxiety are related to poorer
cognitive function in adults.17 Individuals who
meet formal diagnostic criteria for depression and
anxiety are at risk for cognitive impairment, partic-
ularly with advancing age.18 Prevalence of major
depressive disorder is estimated to be approxi-
mately 11% in patients with cancer, as compared
with 5% in the general population, although rates
may vary depending on cancer type.19 The preva-
lence of anxiety disorders in cancer patients is
9.8%.20 However, symptomatology withoutmeeting
the Diagnostic and Statistical Manual of Mental
Disorder (DSM IV) criteria for depression and
anxiety is not associated with cognitive impairment
but may be related to the perceived cognitive prob-
lems reported by patients with cancer.21,22
Cancer Therapy- and Cancer-Related Factors
Nearly all types of therapy for cancer have been
associated with deterioration in cognitive function
in patients with cancer, including both systemic
TABLE 1.
Factors that Influence Cognitive Function in Patients with Cancer
Demographic Psychological
Cancer therapy and
cancer-related factors
Disease- and treatment-related
symptoms
Years of education
General intelligence
Age
Gender
History of:
Neuropsychological disorder
Psychiatric illness
Developmental disorders
Substance abuse
Prior cancer therapy
Depression
Anxiety
Systemic therapies (ie, chemotherapy,
hormonal therapy, biotherapy)
Local therapies (ie, radiation therapy and
surgery)
Dose and duration of therapy
Concurrent therapies
Direct delivery to
central nervous system
Anemia
Fatigue
Pain
Sleep disturbances
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(chemotherapy, hormonal therapy, and bio-
therapy) and local (radiation therapy and surgery)
treatments. The risk for decline in cognitive func-
tion with cancer therapy increases with higher
doses of therapy, longer duration of therapy,
concurrent chemoradiation or chemotherapy
administered after radiation to the brain, and
therapy delivered directly to the central nervous
system.16 Existing evidence also suggests that
priming patients with information about the poten-
tial for decline in cognitive function with therapy is
associated with greater likelihood of self-reporting
such problems.23
Deterioration in cognitive function has been
associated with chemotherapy in multiple popula-
tions of adults with cancer,3,24,25 including women
with breast3,6,24 and ovarian cancer,26 men with
testicular cancer,27 and adults with non-small
cell lung cancer28 and primary malignant brain
tumors.29 Cognitive domains found to deteriorate
with chemotherapy include attention, learning
and memory, psychomotor efficiency, and execu-
tive function.30 Hormonal therapy also has been
associated with deterioration in cognitive function
in both men and women. In women with breast
cancer receiving hormonal therapy, deficits in
verbal4,31-34 and visual memory,4,32,35 psycho-
motor speed,33-36 visuospatial ability,32,35 and
executive functioning35,36 have been reported.
Deteriorations in attention, learning and memory,
executive functioning, and visuospatial ability also
have been observed with androgen deprivation
therapy in men with prostate cancer.37-40
Although less well-documented, deterioration in
cognitive function also has been associated with
biotherapy agents such as interferon therapy.41,42
Radiation therapy administered to the brain has
been associated with cognitive dysfunction in both
adults and children. Most of this research has
involved patients with primary malignant brain
tumors, but these relationships also have been
documented in patients with metastatic brain
lesions from primary breast and non-small cell
lung cancers, and from cancer of the head and
neck. Deterioration in learning and memory, exec-
utive functioning, psychomotor efficiency, and
verbal ability have been associated with radiation
therapy.43-46
Surgery and anesthesiamay contribute to poorer
cognitive function inwomenwith breast cancer. Of
the few investigations of cognitive function related
to cancer surgery, Cimprich found poorer
‘‘capacity to direct attention’’ in womenwith breast
cancer 15 days after breast-conserving surgery or
mastectomy.47 Poorer capacity to direct attention
was associated with greater extent of breast cancer
surgery and older age, particularly in women ages
65 to 79 years.47 Poorer post-surgery cognitive
function in non-cancer populations is predicted
by older age,48 use of general anesthesia,49 and
poorer physical status, according to the American
Society of Anesthesiologists.48,50 More research is
needed to examine the effect of surgery and anes-
thesia on cognitive function in patients with
cancer. This need is particularly relevant because
some patients with cancer exhibit poorer cognitive
function before the initiation of systemic cancer
therapy.
Results from several longitudinal studies of
cognitive function associated with cancer therapy
that included pretreatment assessments revealed
that some adults with cancer have poorer cogni-
tive function before the initiation of systemic
adjuvant therapy compared with healthy in-
dividuals.7,8,24,51 Poorer pretreatment cognitive
function has been observed in patients with
breast,8,24 prostate,51 and lung cancer.52 Several
factors may contribute to pretreatment changes
in cognitive function, including psychological
(depression or anxiety), persistent effects of
general anesthesia following primary surgery,
and disease-related factors such as extent of
disease. Factors that increase one’s risk for the
development of cancer, such as low-efficiency
efflux pumps, deficits in DNA repair mechanisms
and/or a deregulated immune response also may
contribute to changes in cognitive function that
are present before the initiation of therapy.53
Moreover, the capacity to repair DNA and protect
against oxidative stress is variable in the general
population and this variability may inform the
differences in cognitive function noted in women
with breast cancer.53
DISEASE- AND TREATMENT-RELATED SYMPTOMS
A variety of symptoms related to cancer and
cancer-treatment may be associated with poorer
cognitive function. Strategies to manage these
symptoms, particularly pharmacologic manage-
ment, also may influence cognitive function in
patients with cancer. Disease- and treatment-
related symptoms such as anemia, fatigue, and
pain illustrate this association.
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Anemia can damage any tissue or organ and
cognitive dysfunction and neurological injury
have been reported in cases of severe anemia, indi-
cating that the brain is susceptible to anemia-
induced injury.54 More than 30% of patients with
cancer experience anemia with a greater incidence
in certain types of cancer treatments and progres-
sive disease. 55 The causes of anemia include infil-
tration of bone marrow by malignant cells, altered
hemoglobin production related to radiation or
chemotherapy treatments, iron deficiency, or low
endogenous erythropoietin levels.56 Cancer and
treatment-related risk factors especially associated
with anemia include certain tumor types, myelo-
suppressive chemotherapy or radiation therapy,
platinum-based chemotherapies, and low hemo-
globin levels before initiation of treatment.56
Thirty-six percent of colorectal cancer patients
reported cognitive problems before initiation of
chemotherapy, and 52% of these patients reported
experiencing fatigue.57 Cella et al58 reported that
anemic patients with cancer reported significantly
higher levels of fatigue than non-anemic patients
with the disease who, in turn, reported signifi-
cantly higher levels of fatigue than the non-
cancer population. Thus, although anemia is
a factor that may contribute to high levels of
fatigue, it is not the only factor that contributes
to the development of this symptom. Other
factors related to the incidence and severity of
fatigue in patients with cancer include body
mass index, clinical stage, menopausal status,
duration of endocrine therapy, physical activity,
and diet.59
Pain frequently accompanies cancer, particu-
larly in advanced disease, as well as specific cancer
therapies. Results from a meta-analysis showed
that greater than 50% of patients with cancer
(across disease types and stages) reported experi-
encing pain.60 A review by Moriarty et al61 re-
vealed that individuals experiencing pain showed
poorer cognitive functioning in the domains of
attention, learning and memory, processing
speed, and executive functioning compared with
those not experiencing pain. While the mecha-
nistic relationship of pain and cognitive function
is unclear, some have suggested brain morpho-
logic or electrophysiological alterations may
mediate this relationship.61 In addition, use of
some analgesic agents is associated with poorer
cognitive function in patients with cancer.61
Sleep disturbances are commonly experienced
by cancer survivors.62 Increasing age, irregular
sleep/wake schedules, depression, anxiety, symp-
toms (ie, pain, fatigue, nausea and vomiting),
changes in hormone and cytokine secretion,
cancer therapies, and medications such as analge-
sics, antidepressants, antiemetics, anxiolytics,
and corticosteroids contribute to sleep distur-
bances in patients with cancer. Disease-related
factors also may play a role in disrupting sleep
through altered circadian rhythms and the HPA
axis regulatory processes before therapy.63 In the
general population, deteriorations in cognitive
function are associated with sleep disturbances;
experimental studies have revealed that sleep
disruption impairs psychomotor vigilance and
learning and memory.64-66 Results from a study of
adult survivors of childhood cancer showed that
evenmany years after diagnosis and therapy, survi-
vors are significantly more likely than siblings to
report poor sleep quality and score poorer on neu-
rocognitive functioning tests.67
CONCLUSION
More research is needed to explicate the
complex bases for the changes in cognitive func-
tion experienced by patients with cancer. Some
have suggested that the term ‘‘chemobrain’’ leads
health care providers to underestimate the
complex nature of this problem68 and may limit
the scope of their assessment of the potential
factors that may influence changes in cognitive
function in patients with cancer. Nurses must
appreciate the multiple factors that influence
cognitive function in patients with cancer to guide
the assessment and management of the problem.
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Perception of Trauma in Young Adult Survivors of Adolescent Cancer: A Pilot Study 
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Objective: Describe the perception of trauma (Posttraumatic Stress and Posttraumatic Growth) in young 
adult survivors of adolescent cancer. 
Significance & Purpose: Studies have reported higher levels of posttraumatic stress (PTS) in cancer 
survivors than healthy controls while others, however, have reported the occurrence of posttraumatic 
growth (PTG).    Traditionally it has been assumed that the experience was either negative (PTS) or 
positive (PTG) and not able to occur concurrently. Thus, the purpose of this pilot study was to examine 
young adult survivors of adolescent cancer’s perception of cancer as trauma. 
Methods & Analysis: A cross-sectional descriptive pilot study is underway to explore young adult 
survivors of cancer’s perception of cancer as trauma.  Survivors of adolescent cancer are recruited from 
a large pediatric hospital’s outpatient Hematology/Oncology clinic.   Participants must be diagnosed 
with cancer between the ages of 15 and 21, are two or more years after completion of cancer therapy, 
and have no evidence of disease recurrence.  PTS is assessed using the reliable and valid Posttraumatic 
CheckList- Civilian Version (PCL-C) and PTG using the Posttraumatic Growth Inventory (PTGI).  
Descriptive statistics were conducted to characterize the incidence of PTS and PTG in this sample, and 
means, standard deviations, and scatterplots will be reported on the complete sample. 
Findings & Interpretations: To date, 4 subjects of planned sample of 10 have been enrolled.  Symptoms 
of PTSD (M=29.50, SD=8.69) were reported in addition to areas of PTG (M=68.50, SD=7.37).  The most 
commonly reported PTS symptom is persistent avoidance (M= 12.00, SD=3.16).  The most commonly 
reported areas of PTG are Relating to Others (M=26.75, SD=1.71) and Appreciation for Life (M=11.00, 
SD=2.16). 
Discussion & Implications: Early preliminary data indicates the presence of PTS as well as areas of PTG 
suggesting that the two may co-occur.  The cancer experience may trigger perceptions of personal 
growth, even with concurrent reports of distress associated with the cancer experience.   We project a 
sample size of 10 participants to be included and presented in the analysis. This pilot study will provide 
critical information to design larger studies examining PTS and PTG in survivors of adolescent cancer. 
Advancing the knowledge of developmentally appropriate psychosocial care in this subpopulation of 
survivors warrants further attention in the literature. 
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Posttraumatic Responses in Young Adult Survivors of Adolescent Cancer: A Pilot Study 
Bethany Thelen, BSN, RN1 Jean M. Tersak, MD2, Aimee Costello, RN, MSN, PPCNP-BC2 and Margaret 
Rosenzweig PhD, CRNP-C, AOCN1 
1University of Pittsburgh School of Nursing 
2Children’s Hospital of Pittsburgh of UPMC 
 
Aims: High levels of posttraumatic stress (PTS) or posttraumatic growth (PTG) are reported in cancer 
survivors, though incidence and contributing factors have not been explored.  Specific cancer types may 
influence this experience.  This study aims to: 1) Describe incidence of Posttraumatic Stress and 
Posttraumatic Growth in young adult survivors of adolescent cancer; and 2) Explore differences in levels 
of Posttraumatic Stress and Posttraumatic Growth between survivors of leukemia versus lymphoma. 
Methods: A cross-sectional descriptive pilot study was conducted.  Participants (N=12) were diagnosed 
with leukemia (n=5) or lymphoma (n=7) between ages 15 and 21, were 2+ years after completion of 
therapy, without recurrence.  PTS was assessed using the Posttraumatic CheckList- Civilian Version (PCL-
C) and PTG using the Posttraumatic Growth Inventory (PTGI).  Analysis included descriptive statistics and 
an independent samples t-test. 
Results: Symptoms of PTS (M=25.25, SD=9.78) and PTG (M=55.67, SD=25.50) were reported.  Adult 
survivors of leukemia reported significantly greater Avoidant PTS symptoms (t(10)=1.48, p=.043), Hyper-
arousal PTS symptoms (t(10)=1.30, p<.001), and overall levels of PTS (t(10)=1.25, p=.012) than did 
survivors of lymphoma. 
Conclusions: Findings suggest PTS and PTG may co-occur in young adult survivors of adolescent cancer.  
Moreover, survivors of leukemia experienced significantly more Avoidant and Hyper-arousal symptoms 
of PTS, as well as total levels of PTS than survivors of lymphoma.   Larger studies examining PTS and PTG 
in survivors of adolescent cancer are needed to elucidate potential predictors, including disease, 
treatment, and aspects of the cancer experience, and develop interventions which would maximize PTG 
and minimize PTS. 
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Abstract
Purpose Previous research has explored occupational activity
of breast cancer survivors but has not examined the influence
of occupational level on symptoms prospectively. The pur-
pose of this study was to examine the relationship between
occupational classification and changes in mood and symp-
tom burden for postmenopausal breast cancer survivors during
the first year of anastrozole therapy.
Methods This was an exploratory secondary analysis in 49
postmenopausal women receiving anastrozole therapy for
early-stage breast cancer. Participants reported their occupa-
tion at baseline and completed self-report questionnaires mea-
suring mood and symptom burden at baseline, 6 months, and
12 months. Occupation was classified according to four major
skill levels delineated by the International Standard
Classification of Occupations (ISCO).
Results Breast cancer survivors employed at occupational
skill levels 1 through 3 reported significantly higher depres-
sive symptoms, fatigue, and total symptoms on average than
those employed at ISCO skill level 4. After adjusting for mul-
tiple comparisons, this pattern remained for the musculoskel-
etal, vasomotor, and gastrointestinal symptom subscales.
Conclusions Breast cancer survivors employed at lower skill
levels (i.e., ISCO 1–3) reported poorer mood and greater
symptom burden than breast cancer survivors employed at a
higher skill level (i.e., ISCO 4). Assessing baseline occupation
of occupationally active breast cancer survivors may improve
understanding of the association between types of occupations
and mood and symptom trajectories and may inform develop-
ment of interventions to mitigate symptom severity in order to
help breast cancer survivors maintain optimal occupational
function and adherence to therapy.
Keywords Occupational skill . Employment . Cognitive
function . Breast cancer survivors . Anastrozole therapy
Introduction
Returning to and sustaining employment for cancer survivors
is challenging indeed; approximately 40 % of all cancer sur-
vivors never return to work [1]. Of cancer survivors who re-
main working, up to 13 % stop working within 4 years of
diagnosis [2]. Three main categories of factors influence can-
cer survivors’ ability to return to work and maintain pre-
diagnosis occupational roles: disease- and treatment-related
factors (e.g., cancer site, disease stage, treatment, symptoms),
work-related factors (e.g., workload, job demands, social cli-
mate, employer support), and person-related factors (e.g., age,
gender, education level) [1, 3, 4]. Disease- and treatment-
related symptoms may influence the ability of cancer survi-
vors to return to work, maintain pre-diagnosis levels of work
productivity, and advance in careers. Disability and unem-
ployment in cancer survivors result in lost potential and tre-
mendous personal and societal costs. Few studies have exam-
ined the relationship between disease and treatment symptoms
and the ability to maintain occupational roles, and no studies
to date have examined this relationship in postmenopausal
women during aromatase inhibitor (AI) therapy for early-
* Catherine M. Bender
cbe100@pitt.edu
1 School of Nursing, University of Pittsburgh, 415 Victoria Bldg.,
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stage breast cancer. Understanding the relationship between
work-related factors and symptoms is crucial in preventing
work disability, maintaining occupational roles, and achieving
career potential.
Annually, over 100,000 postmenopausal women in the
USA are diagnosedwith estrogen receptor-positive breast can-
cer, the most common breast cancer diagnosis [5]. This type of
cancer is commonly treated with AI, an endocrine therapy
prescribed after initial surgery and taken daily for 5 or more
years; since AI are taken orally and often without concurrent
chemotherapy, many maintain occupational roles during treat-
ment. Thus, breast cancer survivors receiving AI are an ideal
cohort to study when examining factors that may influence the
symptom experience and maintenance of occupational roles
throughout active cancer treatment.
Aromatase inhibitors have side effects including changes in
mood, cognitive complaints, dyspareunia, diarrhea, gyneco-
logical complaints, hot flashes, arthralgia, and musculoskele-
tal difficulties including osteopenia and fractures [6–8]. These
symptoms are not usually severe enough to be dose-limiting
but may be bothersome and affect employment. In the general
population, mood disorders (e.g., anxiety, depression) are a
major cause of loss in work productivity [9]. Fatigue is an
independent predictor of a cancer survivors’ ability to return
to work [4]. The relationship between disease- and treatment-
related symptoms and women’s occupational role may depend
on each woman’s day-to-day activities. The International
Standardized Classification of Occupations (ISCO) has
grouped occupations into four skill levels based on the general
physical and cognitive requirements associated with occupa-
tional role [10].
Work-related factors are complex and multifactorial.
However, evaluation of job classification and the accompany-
ing tasks involved is an important step in clearly understand-
ing which cancer survivors may have greatest difficulty in
maintaining occupational roles. Studies examining employ-
ment rarely take into consideration how cancer and its treat-
ment may interfere with a survivor’s ability to perform certain
job tasks. One study examining job tasks in men with prostate
cancer found increased difficulty in maintaining occupational
roles particularly when the jobs involved highly physical tasks
[11]. Difficulty concentrating and learning new things were
also associated with maintenance of occupational roles [11].
Previous studies of breast cancer survivors who maintained
occupational roles found that they experienced greater age-
adjusted work limitations than non-cancer controls; moreover,
these limitations were predicted by fatigue level [12] and
patient-reported cognitive limitations at work [13]. No study
prospectively examined the role of symptoms in maintenance
of occupational roles for breast cancer survivors. This study’s
aims were to (1) examine differences in changes in mood
(depressive symptoms and anxiety) for breast cancer survivors
during the first year of AI therapy between occupational
classifications (skill level 4 versus skill levels 1–3) before
therapy and (2) examine differences in changes in reported
symptom burden during the first year of AI therapy between
those employed at skill level 4 and those employed at lower
skill levels (skill levels 1–3) before therapy.
Methods
This study was part of a larger longitudinal study, approved by
the University of Pittsburgh Institutional Review Board, and
examines cognitive function in postmenopausal women with
early-stage breast cancer receiving AI therapy (R01
CA107408). Informed consent was obtained from all individ-
ual participants included in the study. Recruitment occurred
between 2005 and 2012 through the University of Pittsburgh
Cancer InstituteMageeWomen’s Breast Cancer Program. The
parent study assessed cognitive function at baseline (pre-AI
therapy) and at 6 and 12 months after therapy initiation. Data
for the current study are drawn from the baseline, 6-month,
and 12-month assessments.
Participants
Parent study inclusion criteria were women who were postmen-
opausal with breast cancer stages I–IIIa, post-surgery, age
≤75 years, able to speak and read English, educated for ≥8 years,
without history of neurological illness or previous cancer (except
non-melanoma skin cancer), not currently receiving hormone
replacement therapy, and not hospitalized for psychiatric illness
within 2 years. The subset of women considered for inclusion in
this secondary analysis received AI without chemotherapy
(n= 158) and had completed symptomquestionnaires at baseline
(i.e., pre-AI therapy) and at 6 and 12 months post-AI initiation.
They also reported at baseline that they were currently employed
outside the home. After applying these criteria, 49 women were
included in our analysis.
Instruments
Demographic and clinical characteristics
Participants completed a demographic questionnaire at base-
line, which assessed age, race, marital status, education, em-
ployment, and occupation. Clinical characteristics were col-
lected and verified using medical records.
Occupational classification
Participants reported their occupation on a baseline demo-
graphic questionnaire, which was re-coded using the ISCO
[14] skill level, which formed fewer, more homogenous
groups in terms of the tasks/skills required. This allowed for
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simpler and meaningful comparisons across skill groupings.
The ISCO has four distinct occupational skill levels.
Skill level 1. Skill level 1 [14] occupations typically involve
performance of simple and routine physical or
manual tasks and may require physical strength
and/or endurance. Some skill level 1 jobs require
basic literacy or numeracy, but this is not amajor
component of the work. Examples of skill level
1 occupations include cleaners, freight handlers,
garden laborers, and kitchen assistants.
Skill level 2. Skill level 2 [14] occupations typically involve
performance of tasks such as operating ma-
chinery/equipment, driving vehicles, mainte-
nance of electrical and mechanical equipment,
and manipulation, ordering, and storage of in-
formation. Many skill level 2 occupations re-
quire relatively advanced literacy and numer-
acy, good interpersonal communication, and a
high level of dexterity. Examples of skill level
2 occupations include butchers, bus drivers,
secretaries, clerks, sales assistants, police offi-
cers, hairdressers, electricians, and mechanics.
Skill level 3. Skill level 3 [14] occupations typically involve
performance of complex technical and practi-
cal tasks using extensive factual, technical, and
procedural knowledge in a specialized field.
Skill level 3 occupations generally require a
high level of literacy and numeracy and well-
developed communication skills, including the
ability to understand complex written material,
prepare reports, and communicate with dis-
tressed individuals. Examples of skill level 3
occupations includemanagers, laboratory tech-
nicians, legal secretaries, commercial sales rep-
resentatives, and computer technicians.
Skill level 4. Skill level 4 occupations typically involve per-
formance of tasks requiring complex problem
solving and decision-making based on exten-
sive theoretical and factual knowledge in a spe-
cialized field. Occupations at skill level 4 gen-
erally require advanced literacy and numeracy
and excellent communication skills, including
the ability to understand complex written ma-
terial and communicate complex ideas in writ-
ing and orally. Examples of skill level 4 occu-
pations include sales managers, engineers, sec-
ondary education teachers, doctors, nurses, and
computer system analysts.
For this analysis, skill levels 1 to 3 were considered as one
group due to sample distribution and compared to skill level 4.
Higher skill levels involve greater complexity and range of
tasks. Skill level 4 occupations typically necessitate, at mini-
mum, a bachelor’s degree, while lower skill level occupations
often require an associate’s degree, vocational training, or
high school education. Individuals with at least bachelor’s
degrees generally have occupations requiring higher skill level
[10]; thus, women in occupational roles that require skill level
4 may experience different difficulties than breast cancer sur-
vivors in lower skill level occupations, given the complexity
required to maintain these occupational roles.
Depressive symptoms
Symptoms of depression were assessed using the Beck
Depression Inventory-II (BDI-II) [15], a 21-item Likert scale
questionnaire measuring affective and somatic depressive
symptoms. Total scores range from 0 to 63, with higher scores
indicating greater depressive symptoms. The BDI-II has high
internal consistency (Cronbach’s alpha = 0.91) [16] and 1-
week test-retest reliability (Pearson’s r = 0.93) [15], indicating
that it is not overly sensitive to daily mood variations.
Anxiety
Anxiety symptoms were measured using the Profile of Mood
States-Short Form (POMS-SF) tension-anxiety subscale,
which has good internal consistency (Cronbach’s alpha = 0.80)
and product moment correlation (Pearson’s r = 0.85) in a
sample of breast cancer patients [17]. The tension-anxiety
subscale consists of nine items with total subscale scores rang-
ing from 0 to 36, with higher scores indicating greater anxiety.
Fatigue
Fatigue was measured using the POMS-SF fatigue-inertia
subscale, which has been used to measure fatigue in cancer
patients with excellent internal consistency (Cronbach’s al-
pha = 0.89) [17], 48-h test-retest reliability (Pearson’s
r = 0.74), and construct validity demonstrated through
interinstrument correlational analysis with other subscales of
the POMS-SF explaining 83 % of the variance in responses
[18]. The fatigue-inertia subscale consists of seven items with
total subscale scores ranging from 0 to 28, with higher scores
indicating greater fatigue.
Symptom experience
Symptom burden was measured using the 42-item Breast
Cancer Prevention Trial (BCPT) checklist [19, 20], which
measures symptoms during breast cancer treatment [20].
There are eight subscales, each representing a clinically rele-
vant cluster of symptoms, cognitive, musculoskeletal, vaso-
motor, nausea, vaginal, sexual, bladder, and body image. Total
scores on the BCPT range from 0 (no symptoms) to 168
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(extremely bothersome symptoms). The BCPT subscales
demonstrated adequate internal consistency (Cronbach’s al-
pha greater than 0.70), except the gastrointestinal symptoms
(Cronbach’s alpha = 0.624), dyspareunia (Cronbach’s al-
pha = 0.618), weight problems (Cronbach’s alpha = 0.616),
and gynecological symptoms (Cronbach’s alpha = 0.557). To
be included in the analysis, women had to have answered at
least 80 % of the items that made up each score.
Data analysis
Standard descriptive statistics and frequency distributions were
generated to characterize the total sample as well as the two skill
level groups. We assessed for differences in demographic and
clinical characteristics between the skill level groups using two-
sample t tests for continuous variables and Fisher’s exact tests for
categorical variables. To test the aims of the study, we used a
repeated measures multivariate analysis of covariance (RM-
MANCOVA). The assumptions for homogeneity of group
variance-covariancematrices were not satisfied for age and years
of education. The assumptions of normality of residuals were
met for all independent variables in our model except for years
of education, but RM-MANCOVA is robust against violations of
normality. To improve the distribution of residuals, we consid-
ered the applications of the square root and log base 10 transfor-
mations to the data. Analyses using transformed data did not
change the conclusions drawn; thus, we reported results from
untransformed data in their original scaling.
We conducted a RM-MANCOVA to examine relationships
between occupational skill level andmood (i.e., scores for BDI-
II, POMS tension-anxiety subscale) at baseline, 6 months, and
12 months, after controlling for years of education as a covar-
iate in the model since this was significantly different between
the skill level groupings. We examined polynomial contrasts
and added a covariate, age, for the analysis of depressive symp-
toms [21]. Assumptions of the RM-MANCOVA method (i.e.,
normality, linearity, sphericity, homogeneity of regression
slopes, and reliable measurement of the covariate) [22] were
met for dependent variables in the model. To protect against
inflation of type I error when looking at multiple dependent
variables, we first examined the results of multivariate tests,
and only if the multivariate test was statistically significant
did we proceed to look at results of the univariate tests to see
which variables, more specifically, demonstrated statistical sig-
nificance. For aim 2, we used a RM-MANCOVA to examine
changes over time in reported symptom burden overall as well
as by specific symptom domains by those employed at skill
level 4 and those employed at skill levels 1–3. Partial eta-
square values were calculated as a measure of effect size for
groupmean differences. Two-sided hypothesis testing was con-
ducted at the 0.05 significance level using IBM® SPSS®
Statistics, version 22.0 (IBM Corp., Armonk, NY).
Results
Participant characteristics
Table 1 summarizes participant characteristics by skill level
grouping. Approximately 59 % of the samples were employed
Table 1 Demographic and
clinical characteristics at baseline
by occupational group (n = 49)
Characteristic Skill levels 1–3, n = 20
(40.8 %)
Skill level 4, n = 29
(59.2 %)
Test
statistics
p value
Mean (SD) Mean (SD)
Age (years) 59.2 (1.7) 58.2 (0.8) t = 0.54 0.631
Education (years) 13.0 (0.4) 17.0 (0.6) t = 5.18 <.001
Weeks since diagnosis (n = 48) 8.9 (0.8) 8.6 (0.8) t = 0.23 .815
Weeks since first surgery 5.0 (0.5) 5.1 (0.6) t = 0.14 .888
Percent (n) Percent (n)
Married or partnered (yes) 45.0 (9) 72.4 (21) – .075a
White (yes) 100.0 (20) 100.0 (29) – 1.000a
Natural menopause (yes) 70.0 (14) 86.2 (25) – .133a
HRT-ever (yes) 50.0 (10) 51.7 (15) – .568a
Mastectomy (versus BCS) (n = 47) 10.5 (2) 17.9 (5) – .685a
Radiation therapy (yes) (n = 46) 84.2 (16) 92.6 (25) – .635a
Stage of disease
I 90.0 (18) 89.7 (26) – .486a
IIa 10.0 (2) 3.4 (1) – –
IIb 0.0 (0) 6.9 (2) – –
SD standard deviation, HRT hormone replacement therapy, BCS breast-conserving surgery
a Fisher’s exact test
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at skill level 4, while the rest were employed at skill levels 1
through 3. As expected, women employed in occupations at skill
level 4 had significantly more education (p < .001) than women
employed in lower skill level occupations. Thus, years of educa-
tion was included as a covariate in our model. No other signif-
icant differences between occupational skill groups were found.
Occupational skill level and mood
RM-MANCOVA examining the relationship between subjects’
skill level group and their mood at baseline, 6 months, and
12 months after beginning AI therapy showed a main effect
of group on mood, F(2,45) = 4.86, p = .01, partial η2 = 0.178.
Compared to individuals employed at skill level 4, those
employed at the lower skill levels reported significantly higher
anxiety and depressive symptoms on average. The levels of
anxiety (p = .46) and depressive symptoms (p = .17) did not
significantly vary over time. Analysis revealed significant dif-
ferences in the level of depressive symptoms between lower
skill levels and skill level 4 over the first year of AI therapy,
F(1,47) = 4.29, p = .04, partial η2 = 0.09 (Fig. 1), but no
significant differences for anxiety (see Table 2).
*adjusted for age. Age=58.61
Fig. 1 Trajectory of treatment-related symptoms in the first year of anastrozole therapy
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Occupational skill level and symptom experience
Total BCPT symptom scores and fatigue levels demonstrated a
time effect,F(2,94) = 17.0, p < .001, partial η2 = 0.266, and group
effect, F(2,94) = 4.9, p = .009, partial η2 = 0.095. The univariate
tests for time, however, showed that only total BCPT had a sig-
nificant time effect, p < .001, partial η2 = 0.181 (see Table 3). The
test of between-subject effects showed that there are significant
between group differences for both fatigue, p = .009, η2 = 0.169,
and total BCPT, p = .023, partial η2 = 0.105 (see Fig. 1). More
specifically, those at skill levels 1 through 3 reported significantly
higher levels of fatigue and total symptom scores and this pattern
persisted over the 1-year time period.
When exploring differences between the two occupational
skill levels and the specific symptom domains of the BCPTover
time using RM-MANCOVA, we found a significant time effect,
F(16,28) = 3.4, p = .002, partial η2 = 0.661, and group effect,
F(8,36) = 2.9, p = .014, partial η2 = 0.390. As summarized in
Table 3, univariate tests revealed that musculoskeletal symptoms
(p < .001), vasomotor symptoms (p = .001), dyspareunia
(p < .001), bladder problems (p = .017), and weight concerns
(p = .011) worsened over the 1-year study time frame. The test of
between-subject effects showed that those employed at skill
levels 1 through 3 reported significantly more severe musculo-
skeletal (p = .005), vasomotor (p = .028), and gastrointestinal
(p = .010) symptoms than those employed at skill level 4 (see
Fig. 1). Though results were not statistically significant for each
of the other BCPT subscales, it is worth noting that mean symp-
tom burden scores for skill levels 1 through 3 were consistently
higher across all three time points for cognitive complaints, mus-
culoskeletal symptoms, vasomotor symptoms, gastrointestinal
symptoms, bladder control, and weight concerns.
Discussion
This study suggests that occupational skill level is associated
with mood and symptom burden in women receiving AI therapy
for breast cancer, with a small effect size. In this longitudinal,
observational study, women employed at skill levels 1 through 3
reported higher anxiety and depressive symptoms than those
employed at the higher skill level (4). Women at lower skill
levels also reported higher levels of symptom burden associated
with AI therapy including fatigue, musculoskeletal complaints,
vasomotor symptoms, gastrointestinal problems, and total symp-
tom burden. From baseline through the first year of therapy,
symptom burden related to AI therapy worsened for both skill
level groupings. However, women in the lower skill level group-
ing reported more severe symptom burden than those employed
at the higher level in six (cognitive complaints, musculoskeletal
symptoms, vasomotor symptoms, gastrointestinal symptoms,
bladder control, and weight concerns) out of eight symptom
subscales on the BCPTat each of the three time points measured
in the study (baseline, 6 months, and 12 months).
Findings suggest that women employed at lower skill levels
may be more bothered by symptoms during the first year of AI
therapy, which might be related to lower skill levels typically
involving high levels of physicality. It is also possible that wom-
en employed at lower skill levels may not have as comprehen-
sive a benefit package or receive accommodations as easily as
women employed at the highest skill level. With fewer benefits,
those employed at lower skill levels may not be eligible for paid
time off to attend appointments to adequately address symptoms
or may not have employers as willing to implement workplace
accommodations, which may contribute to poorer mood and
more bothersome symptoms [23–26]. Future research should
investigate why breast cancer survivors employed at lower skill
levels reported more bothersome symptoms than those
employed at skill level 4. Future work should develop interven-
tions to mitigate symptom burden for women beginning AI ther-
apy who wish to maintain their occupational roles.
Results of this study may inform future studies of mood and
symptom experience in women receiving AI for early-stage
breast cancer. This study suggests a proxy variable to help
predict which breast cancer survivors may experience more
severe symptoms and difficulty maintaining occupational roles
Table 2 Occupational skill level
and mood over time Mood Skill levels 1–3,
n = 20 (40.8 %)
Skill level 4,
n = 29 (59.2 %)
Test statistics p value
Mean (SD) Mean (SD)
Depressive symptoms
Baseline 7.9 (8.4) 3.9 (2.7) FGroup(1,46) = 8.91 .005
6 months 8.5 (9.4) 2.5 (2.3) FTime(2,92) = 0.68 .512
12 months 8.3 (9.9) 4.2 (4.3) FGroup × Time(2,92) = 1.83 .166
Anxiety
Baseline 8.0 (6.1) 6.6 (3.6) FGroup(1,46) = 2.77 .103
6 months 8.2 (7.4) 5.4 (3.6) FTime(2,92) = 0.72 .487
12 months 7.0 (7.6) 5.1 (4.8) FGroup × Time(2,92) = 0.79 .456
SD standard deviation
Support Care Cancer
from diagnosis through early treatment and survivorship.Many
clinics routinely screen for symptom severity at office visits,
but it is often unclear how the trajectory of mood and symp-
toms in a patient will develop over time. This study suggests
that assessment of the woman’s occupation at baseline may
help predict the severity of symptoms throughout the first year
of treatment. Knowing the likely course of symptom severity
before treatment provides a window of opportunity to counsel
Table 3 Occupational skill level
and symptom burden over time Symptom Skill levels 1–3 Skill level 4 Test statistics p value
Mean (SD) Mean (SD)
n = 20 (40.8 %) n = 29 (59.2 %)
Fatigue
Baseline 9.6 (8.8) 3.7 (3.2) FGroup(1,47) = 9.56 <.001
6 months 6.8 (6.0) 3.6 (3.7) FTime(2,94) = 1.95 .009
12 months 8.2 (8.9) 4.0 (3.5) FGroup × Time(2,94) = 9.56 .003
Total BCPT
Baseline 22.4 (20.1) 14.5 (8.5) FGroup(1,47) = 5.54 .023
6 months 27.3 (22.3) 16.3 (10.0) FTime(2,94) = 10.42 <.001
12 months 30.9 (23.9) 18.9 (11.3) FGroup × Time(2,94) = 1.18 .311
n = 17 (37.8 %) n = 28 (62.2 %)
Cognitive
Baseline 2.1 (3.0) 1.5 (1.5) FGroup(1,43) = 1.08 .304
6 months 2.2 (2.6) 1.3 (1.7) FTime(1.6,69.4) = 0.19 .784
12 months 2.1 (2.4) 1.8 (1.8) FGroup × Time(1.6,69.4) = 0.83 .418
Musculoskeletal
Baseline 3.9 (3.2) 2.3 (2.3) FGroup(1,43) = 8.91 .005
6 months 5.6 (4.2) 3.0 (2.7) FTime(2,86) = 8.39 <.001
12 months 6.4 (4.3) 3.4 (2.8) FGroup × Time(2,86) = 1.28 .285
Vasomotor
Baseline 2.1 (2.8) 1.3 (1.2) FGroup(1,43) = 5.19 .028
6 months 3.3 (3.0) 1.9 (1.7) FTime(2,86) = 7.90 .001
12 months 3.8 (3.5) 1.9 (1.4) FGroup × Time(2,86) = 1.36 .261
Gastrointestinal
Baseline 0.5 (1.1) 0.1 (0.4) FGroup(1,43) = 7.18 .010
6 months 0.8 (1.0) 0.3 (0.8) FTime(1.7,72.8) = 2.73 .080
12 months 1.1 (1.7) 0.3 (0.8) FGroup × Time(2,86) = 0.79 .437
Dyspareunia
Baseline 0.4 (0.8) 1.4 (2.1) FGroup(1,43) = 3.44 .071
6 months 1.0 (2.0) 2.1 (2.4) FTime(1.6,69.3) = 10.44 <.001
12 months 1.4 (1.9) 2.4 (2.3) FGroup × Time(2,94) = 0.00 1.0
Bladder control
Baseline 1.1 (1.9) 0.5 (0.7) FGroup(1,43) = 3.02 .090
6 months 1.4 (2.1) 0.6 (1.0) FTime(1.6,68.1) = 4.78 .017
12 months 1.8 (2.5) 0.8 (1.5) FGroup × Time(1.6,68.1) = 1.07 .336
Weight concerns
Baseline 1.9 (2.4) 1.3 (1.4) FGroup(1,43) = 1.68 .202
6 months 2.4 (2.2) 1.5 (1.8) FTime(2,86) = 4.8 .011
12 months 2.6 (2.4) 2.0 (1.8) FGroup × Time(2,86) = 0.32 .725
Gynecological
Baseline 0.2 (0.6) 0.3 (0.5) FGroup(1,43) = 0.02 .904
6 months 0.4 (0.6) 0.4 (0.8) FTime(2,86) = 0.40 .675
12 months 0.4 (0.7) 0.3 (0.7) FGroup × Time(2,86) = 0.02 .942
SD standard deviation, BCPT Breast Cancer Prevention Trial Symptom Checklist
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the woman about what she may experience, as well as the
opportunity to develop and implement interventions which
can prevent or treat these symptoms early, before they interfere
with the ability to maintain an occupational role. It would be
incorrect to assume that cancer survivors who remain
employed during and after treatment have less severe symp-
toms and that their symptoms do not increase in severity over
time. This knowledge is important because other studies have
found that severity of symptoms predict poor adherence to
treatment [27, 28] and who will remain employed [12, 24, 29].
Studies of cancer survivors found that physical symptoms,
depression, and fatigue were associated with ability to return
to work [4]. Receiving advice from a healthcare provider
about returning to work improves cancer survivors’ ability to
maintain employment [24, 30]. Given that our study found
significant associations between occupational skill level and
both depression and symptom burden, the development of
interventions aimed at assisting women, particularly those
employed at the lower occupational skill levels, may mitigate
the severity of symptoms experienced and assist them inmain-
taining occupational roles.
Study limitations
The current study has several limitations that are relevant to
data interpretation. First, this study is a secondary analysis of a
larger study collecting longitudinal data of breast cancer sur-
vivors’ cognitive function. The occupational skill level groups
were formed post hoc and additional, unmeasured confound-
ing variables may have been associated with skill level. Skill
level was classified based on participant’s job title at baseline.
For our analyses, we assumed that the occupation reported at
baseline remained unchanged over the first year of AI therapy.
Therefore, we could not evaluate relationships between symp-
tom burden and ability to return to work or stay employed.
Additionally, due to our limited sample size, we were unable
to examine the relationships between symptoms and working
full time or part time. While the relationships between occu-
pational classification and physical and psychological symp-
toms were statistically significant, the effect sizes were small.
Future studies should examine the clinical significance of
these relationships.
Future research should incorporate more sophisticated
instruments of occupational classification and work func-
tion, which may yield a richer picture of occupation and
the tasks involved. These instruments may also assess other
important factors known to affect cancer survivors’ employ-
ment status, including the workplace and employer adapta-
tions [2, 24]. Lastly, given the small sample size and the
distribution of occupational skill level, future research with
a larger sample size and more diverse occupational skill
level classifications should be conducted to confirm find-
ings in this exploratory study.
Conclusion
Despite these limitations, this study offers a unique perspec-
tive on the association between occupational skill level and
the symptom burden of postmenopausal women receiving AI
therapy for breast cancer. This study highlights the importance
of considering the occupation of cancer survivors when
assessing the symptom experience and predicting the degree
of bother associated with symptoms during the first year of
therapy. Future research with a larger, more diverse sample is
needed to assess occupational skill level based on more spe-
cific ISCO occupational classification and to examine what
work tasks and aspects of the work environment are most
associated with mood and symptom severity. Including as a
part of routine clinical care whether or not a breast cancer
patient is employed and, if so, whether she is planning to
continue workingmay add to the ability to examine symptoms
in the context of a woman’s occupation. Clinicians working
with cancer survivors might consider asking about occupa-
tional function and difficulties to gain perspective on what
aspects are most difficult. Finally, it will be important to ex-
pand the findings from our study to other cancer populations
and ultimately formulate efficacious interventions to reduce
symptom severity and assist survivors in maintaining occupa-
tional roles for as long as possible.
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